Characterization of a peptide biomaterial used for cell-seeded scaffolds with an analysis of relevant stem cell policy by Kim, Gina
Characterization of a Peptide Biomaterial Used for Cell-Seeded Scaffolds
with an Analysis of Relevant Stem Cell Policy
By
Gina Kim
B.S. in Mechanical Engineering, Massachusetts Institute of Technology, 2002
Submitted to the Department of Mechanical Engineering
and the Engineering Systems Division
in Partial Fulfillment of the Requirements for the Degrees of
Master of Science in Mechanical Engineering
and
MASSACHUSETTS INSTITUTE.
Master of Science in Technology and Policy OF TECHNOLOGY
J UN 1 6 2005
at the
Massachusetts Institute of Technology LIBRARIES
June 2005 L_ BRARES
K 2005 Massachusetts Institute of Technology. All rights reserved.
Signature of Author
Department of Mechanical Engineering and Technology and Policy Program
May 16, 2005
Certified by---------------------
Roger D. Kamm
Professojof Mechanical Engineering and Bioengineering
Thesis Supervisor
Accepted bybbbbbbbbbbbbbbbbbbbbbbbbbb---------------------------------------
Lallit Anand
Chair, Department Committee on Graduate Students
/\ Dr.parjw ient of Mechanical Engineering
Accepted by ___________------------ _ _- M
t Dava J. Newman
Professor of Aeronautics and Astronautics and Engineering Systems
Director, Technology and Policy Program

Characterization of a Peptide Biomaterial Used for Cell-Seeded Scaffolds
with an Analysis of Relevant Stem Cell Policy
By
Gina Kim
Submitted to the Department of Mechanical Engineering and the Engineering Systems Division
on May 16, 2005 in Partial Fulfillment of the Requirements for the Degrees of
Master of Science in Mechanical Engineering and Master of Science in Technology and Policy
Abstract
Restoring damaged or diseased tissue in the body may involve the use of biomaterial
scaffolds that provide a responsive environment for cell proliferation. Such scaffolds may be
used for in situ cell regeneration, where an implanted scaffold incites cell growth in the body, as
well as for growing artificial tissue in vitro by seeding cells in a scaffold that will be implanted at
a later stage of development or used for physiological tissue models.
The research outlined in this thesis describes two methods of characterizing the stiffness
of a biomaterial scaffold. It is well known that cell growth in vitro is affected by the moduli of
the surrounding scaffold. Stiffness is also cited as a major factor affecting angiogenesis, the
formation of new blood vessels. We describe a new rheometric method to examine the bulk
mechanical properties of a self-assembling peptide biomaterial that spontaneously forms a
filament network in a physiological salt solution and supports cell attachment and differentiation.
This method has two major advantages: first, it reduces the time per sample and second, it can
be used to analyze materials where cross-linkers must be added and washed out. We also have
also used fluorescence microscopy and wrote a program to find the persistence length of actin
filaments in the eventuality that peptide filaments can be reliable isolated.
This self-assembling peptide biomaterial has shown great promise as a scaffold for
differentiated cells and has also been shown to support adult liver stem cells. Therefore it is
likely that it can support human embryonic stem cells. The second half of this thesis describes
the ramifications of the policy decision on August 9, 2001 to limit federal funding to existing cell
lines. We describe the ethical debate and political climate that led to the decision. An
examination of the publication data shows that researchers in the United States have in fact
remained leaders in the field until this point, in part because U.S. federal funding has also been
available to early mover international groups who appear to have abided by the restrictions.
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Chapter 1
Introduction
1.1 Control of Biomaterial Properties
Restoring damaged or diseased tissue in the body may involve the use of biomaterial
scaffolds that provide a responsive environment for cell proliferation. Such scaffolds may be
used for in situ cell regeneration, where an implanted scaffold incites cell growth in the body, as
well as for growing artificial tissue in vitro by seeding cells in a scaffold that will be implanted at
a later stage of development or used for physiological tissue models (Griffith and Naughton,
2002).
One way that scaffolds aid cell growth into tissue is by providing structural support that
simulates the function of the cell's natural extracellular matrix (ECM), which is comprised of
proteins such as collagen, elastin and fibronectin. In vivo, most cells cannot survive unless
attached to the ECM, a phenomenon called anchorage dependence, and adhesion is governed by
integrin receptors, which bind the ECM to cell's cytoskeleton (Sethi et al., 1999). It is believed
that the ECM gives both chemical and physical cues to the cell, though the exact signaling
pathways are not fully understood.
One hypothesis suggests that cells may sense mechanical stimuli directly through the
ECM via a change in the cell's morphology. By attaching to the ECM and flattening out, the cell
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may cause integrins to spatially align, thereby activating a downstream pathway (Boudreau and
Jones, 1999). Another theory focuses on the shear forces that result from interstitial fluid flow
caused by the applied mechanical strain: when the load is applied, portions of the matrix become
compressed, producing pressure gradients that cause flow past the cells. These shear forces may
induce a conformational change in the integrin heterodimers, which may increase their binding to
ECM proteins and activate a signaling cascade (Tzima et al., 2001) or lead to intracellular
conformational changes that alter binding affinities or enzymatic activity.
The research outlined in this thesis concentrates on controlling the stiffness of a
biomaterial scaffold. It is well known that cell growth in vitro is affected by the moduli of the
surrounding scaffold. Chondrocytes may differentiate into fibroblasts in a cultured monolayer,
but if detached and transferred to an agarose gel, they will change back to their original, non-
differentiated spherical shape. They may also re-exhibit chondrocyte characteristics such as
expression of type II collagen (Benya and Schaffer, 1982). Fibroblast growth also differs when
cells are cultured in constrained gels that transmit significant matrix stresses back to the cells, as
opposed to free-floating gels that do not resist cell traction.
Stiffness is also cited as a major factor affecting angiogenesis, the formation of new
blood vessels. Most tissues, including those of the liver and heart, require vasculature to nourish
cells. Therefore the creation of a pre-existing network of blood vessels in a 3-D implantable
scaffold and the ability to incite new vasculature growth in a tissue implant are crucial steps
towards making tissue engineering a reality. Progress in this area requires understanding how
endothelial cells form networks and lumens, a process that seems dependent on matrix stiffness.
Endothelial cells plated on Matrigel of lower stiffness demonstrated increased network formation
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(Kuzaya et al., 1996) and when cultured in type-I collagen, the cells formed different-sized
lumens depending on the stiffness of the gel (Sieminski, Hebbel, & Gooch, 2004).
Thus the stiffness of a surrounding scaffold is a key element of a cell's mechanical
environment, and understanding this material property is crucial for tissue engineering efforts.
13
1.2 Self-Assembling Peptide Biomaterials
The choice of material for tissue engineering scaffolds is an important one, as stiffness is
not the only material property that is important for cell growth. Important parameters include the
chemical composition, architecture (pore size, ordered structure vs. random filaments, etc.),
potential attachment of growth factors, processing stability, biocompatibility, and degradation or
resorbtion rate in the body. These parameters are inter-related; for example, chemical
composition may affect architecture as well as biocompatibility.
Yet depending on the purpose of the research, different design parameters may be
relatively more important than others. For example, for in vitro tissue models, degradation is not
a major concern as long as the scaffold favorably directs cell growth and recreates physiological
conditions, though this in itself is not a trivial problem. But for therapeutic materials intended to
be implanted or injected in the body, degradation or resorbtion rate is a basic requirement as
inflammation usually results from permanent implants (Babensee et al., 1998) if the implant is of
a much higher order stiffness than that of the extracellular matrix (A.L. Sieminski, personal
communication, May 3, 2004).
Both natural and synthetic materials have been explored as biomaterials for therapeutic
uses and in vitro tissue models. Collagen (Vernon et al., 1992), which is secreted by fibroblasts,
or fibrin (Nehls and Herrmann, 1996), which is found in blood clots, or Matrigel, a biologically-
derived material, are commonly used for scaffolds because they are naturally occurring
structures with strength and stiffness moduli that are attractive to cells. But these materials
require the addition of angiogenic and survival factors for cell proliferation, and also may have
problematic consistency and risk of contamination due to their derivation from animals.
Synthetic materials include polyesters from the polylactic (PLA) and polyglycolic (PGA) acid
14
families, and were originally used in sutures and other applications because of their ability to
hydrolytically cleave into CO 2 and H20 in the body (Hench and Polak, 2002). Yet these
materials also require the addition of growth factors and may necessitate relatively complex
manufacturing processes such as 3D printing to fabricate porous structures at the microscale.
Furthermore, they have also been implicated in causing inflammation (Griffith, 2002).
A recently discovered class of biomaterials improves on several of these limitations.
Self-assembling peptides consist of amino acids with alternating hydrophobic and hydrophilic
side-chains. They spontaneously form filaments when put in physiological salt solutions at
concentrations ranging from 1 mg/mL (0.1% by weight) to 10 mg/mL (1% by weight). The
filaments are on the order of extracellular matrix (ECM) fibers, and form a network that supports
cell attachment and differentiation without the addition of growth factors, possibly because the
cells may be producing their own ECM. Scaffold properties may currently be manipulated by
changing peptide sequence and length.
We chose to characterize the materials properties of RAD16-II (AcN-
RARADADARARADADA-CNH 2) because the properties of this peptide gel enable it to direct
the formation of endothelial cells into capillary-like networks that are viable for at least 18 days
(Narmoneva et al., 2004). In addition, the material has been demonstrated to degrade in vivo
(Holmes et al., 2002), and remains a promising and intriguing possibility for transplants and in
vitro cell culture experiments.
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1.3 Bulk Characterization of Material Properties
Tensile tests (Leon et al., 1998) and rheometry (Caplan et al., 2002) have been performed
on the peptide biomaterial itself, while confined compression has been used for peptide seeded
with cells (Kisiday et al., 2004).
Uniaxial tensile tests may be performed on peptide that has been extruded into a salt bath
and allowed to solidify. Young's modulus for EFK8 has been successfully calculated by
measuring forces and displacements that result from pulling on the peptide thread (Leon, 1998).
This method presents several challenges: the peptide thread is fragile at 10 mg/mL
concentrations and fractures after applying small strains of 1.1%-1.3%, though strains of up to
8% have been observed for lower concentrations. In addition, the difficulty in handling the
peptide decreases the number of tests with usable results; only two were performed at the 10
mg/mL concentration.
Mechanical properties of hydrogels have also been characterized using rheometry.
Caplan et al. (2002) first developed a standard method for testing the peptide gels in 2000. The
method has the advantage of using standard equipment, in this case, an AR1000 or AR2000
model rheometer made by TA Instruments (New Castle, DE). Briefly, peptide solution is
pipetted onto the rheometer plate. The cone is lowered and a salt solution is pipetted around the
solution to allow diffusion of salt solution over a period of 15 hours. An oscillatory shear stress
is then applied; the cone allows a constant shear to be applied over the radius of the sample.
Gelled peptide exhibits the properties of a viscoelastic solid for which the loss and storage
moduli are virtually independent of frequency. However, this method has a lengthy set-up
period and results seem to vary depending on how long the peptide is allowed to equilibrate with
16
the salt solution. The procedure was therefore modified for the experiments in this thesis.
Rheometric procedures will be further discussed in Chapter 2.
Kisiday et al. (2002) used confined compression tests to demonstrate that chondrocyte-
seeded gels that undergo dynamic compression have moduli of 97 kPA, 60-70% higher than
free-floating gels. However, using confined compression for hydrogels without cells remains a
challenge as the low moduli are beyond the range of this specially constructed machine. For this
reason, although confined compression gives reproducible and statistically consistent results, we
will use rheometry as our primary methodology to directly characterize the peptide gel.
17
1.4 Microscale Characterization (Fluorescence Microscopy)
Filament stiffness is characterized both directly and indirectly. Direct methods involve
micromanipulation of a filament; for example, Kojima, Ishijima and Yanagida (1994) calculated
the elasticity of actin filaments from force and displacement data resulting from pushing the ends
of filaments with microneedles. Riveline et al. (1997) measured stiffness by using laser tweezers
to manipulate beads attached to actin filaments. Indirect measurements, on the other hand,
derive material properties from observation of filaments under Brownian motion. Gittes et al.
(1993) calculated the flexural rigidity of microtubules and actin filaments by characterizing the
shape of filaments as a sum of cosine modes, then calculating persistence length. Ott et al.
(1993) found the persistence length of actin filaments by observing filaments, then deriving the
correlation function.
Direct measurements depend on the quality of the mechanism and the skill of the
operator; to get a statistically significant result, many filaments must be captured and
manipulated. Indirect measurements require high-resolution imaging and vast computational
power (the Ott experiment analyzed 22,000 images). The precision of imaging depends on the
resolution of the microscope, the quality of the camera and the capabilities of the capture
software. We decided to use an indirect measurement because of the availability of this system
and the relative difficulty of micromanipulation compared to observation.
However, we had limited success in isolating peptide filaments; our results were not
wholly reproducible. Still, for future reference, the attempted procedure is outlined in Chapter 3
with a test analysis of actin filaments, and a Matlab code that analyzes the bending of the
filaments is given in Appendix A.
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1.5 Cross-Linking
Cross-linking has been shown to strengthen biomaterials. Avidin, and its bacterially
derived, tetrameric version streptavidin, are proteins that are commonly used reagents in biology
labs because of their high affinity for biotin (the disassociation constant for the streptavidin-
biotin reaction is approximately KD = 10" M (Green, 1990)). Wachsstock, Schwarz and
Pollard (1994) have cross-linked actin filaments using biotin and avidin and other weaker cross-
linking compounds such as a-actinin. The biotinylated gel had a greatly increased modulus
compared to the control and behaved like an elastic solid, showing no frequency dependence.
Based on these results, we attempted to control the strength of the peptide biomaterial by
biotinylating the filaments and adding streptavidin, which theoretically should have cross-linked
the filaments and strengthened the gel. Our results are presented in Chapter 4.
19
1.6 Policy Analysis
The self-assembling peptide biomaterial has demonstrated great advantages as an in vitro
scaffold for cell culture. Thus far, many cell types have successfully been demonstrated to
proliferate, among them neurons (Holmes et al., 2002), chondrocytes (Kisiday et al., 2002),
cardiac myocytes (Narmoneva et al., 2004), and adult liver stem cells (Zhang, 2002). It is
therefore likely that this biomaterial will also support the growth of human embryonic stem cells.
Stem cells are cells that have the potential to divide and differentiate into other cell types
but also may reproduce themselves upon division (National Institutes of Health, 2001). They are
therefore particularly intriguing to researchers who seek treatments for diseases that result from
abnormal cell dysfunction or death. Parkinson's disease, for example, may be caused when
neurons cease to produce dopamine. But because most adult neural stem cells appear to be
dormant except in specific neurogenic regions of the brain (Abrous, Koehl, & Le Moal, 2005),
new neurons are not usually generated to replace dysfunctional ones. Further, while the
transplantation of embryonic neural cells has proved beneficial to some patients (Freed et al.,
2001), the problem of cellular rejection remains. Ideally, new neural cells intended for
transplantation would have the same genetic material as the adult and develop into cells with
identical markers to minimize the body's immune response. Therefore, by replacing the nuclear
genetic material of a fertilized egg with that of an adult cell, and allowing the egg to develop
normally into a blastocyte, researchers may then extract genetically identical stem cells that can
be coaxed to grow into any type of cell.
Similarly, stem cells could be grown in vitro into replacement organs that could be
conventionally transplanted. Currently the United States faces a severe shortage of transplant
organs. In 2002, 14,741 kidney transplants were performed, but nearly 55,000 people were
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waiting for a kidney. In total, over 88,000 patients were waiting for transplant donations (U.S.
Bureau of Census, 2003). The creation of genetically identical artificial organs has the potential
to ease this shortage, in addition to increasing the one-year survival rate of transplant recipients.
Yet however promising stem cell treatments seem, human embryonic stem cell research
is controversial for two major reasons. First, it requires the destruction of the embryo to harvest
the cells. Second, it is inextricably tied to therapeutic cloning. Chapter 5 will describe the
science of human embryonic stem cell and some common ethical frameworks through which this
technology is viewed.
Yet while the ethics of this issue are fiercely debated, many other nations that have the
scientific infrastructure to support experimentation have legislated their approval of the research
on the national level. In the United States, however, no laws have been ratified to either ban or
allow the research, and restrictions on federal funding are decided solely by the executive, who
at the time of this writing is President George W. Bush. Chapter 6 will seek to identify the
institutional differences that explain why U.S. stem cell policy currently differs from most other
scientifically advanced nations. Finally, critics of the Bush Administration policy, which went
into effect on August 9, 2001 and limits the use of federal funding to hESC lines created before
that day, voiced fears of a "brain drain" where U.S. scientists might choose to go abroad to
pursue their research (Conner, 2002). In addition, some critics maintained that U.S. researchers
would fall behind their international colleagues in terms of innovation and progress (Cook and
Allen, 2004). Chapter 7 will use publication data from the past seven years to evaluate these
assertions and will seek to demonstrate that in fact, because the National Institutes of Health can
grant federal funding to international institutions, it appears that in the past four years, foreign
21
researchers who publish the most notable research have also abided by U.S. federal policy.
Chapter 8 will outline future directions for this analysis.
22
1.7 Thesis Objectives
Aim 1: Develop a method for fast and reliable characterization of the material properties of gels,
especially cross-linked gels.
Previous methods (Caplan et al., 2002) require a lengthy and somewhat cumbersome
procedure in which the peptide must be gelled in place. In addition, it is impossible by this
method to consistently wash out cross-linkers.
Aim 2: Repeatably characterize the rheological properties of peptide gels at different timepoints,
at different concentrations, and after the addition of cross-linkers.
RADA16-1I peptide gel has not been fully or methodically characterized over a variety
conditions that can affect the stiffness of the structure.
Aim 3: Repeatably characterize the microstructure of single peptide filaments.
Characterizing single filament dynamics can provide useful insight into the role
individual filament stiffness plays in determining bulk modulus and other properties.
Aim 4: Define the ethical debate over stem cell research within common philosophical
frameworks and analyze the institutional dissimilarities that have led policy differences between
the United States and other nations.
It is necessary to provide a context for the ethical debate and differing regulations to
clarify and fully understand the debate.
23
Aim 5: Using publication data, identify early trends in important stem cell research. Determine
how U.S. research compares to that of other nations in terms of number of publications and
citation frequency. Analyze the relationship between federal funding and the publication of
novel and important research.
We seek to identify how the Bush Administration federal funding guidelines for hESC
research have actually affected the U.S. research community in comparison to those of other
nations.
24
Chapter 2
Rheometry
2.1 Theory
Rheology is the study of fluid flow. For hydrogels, several quantities may be derived to
characterize a material.
For Newtonian fluids, shear stress T2 1 is proportional to shear strain rate 721. The
resulting constant of proportionality is viscosity p.
121 =U 2i (1)
The ratio of shear stress to shear strain is given by the modulus G, which for most elastic
materials is constant.
121= Gy 21  (2)
Linear viscoelastic materials, which include most hydrogels, exhibit proportionality to
both strain rate and strain. To quantify these materials, the complex modulus G*may be derived:
To obtain more general expressions for a viscoelastic material, one can write a strain
profile for any material by dividing it into time steps ti, t2 .. .tn.
Because of superposition, this strain profile for one-dimensional shear may be written as
y(t) = H(t - t1)Ay + H(t -t 2)Ay 2 + ... (3)
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where H could be any time-dependent function to describe the shear strain (step, linear,
sinusoidal, etc.), The corresponding stress response profile is then, assuming linearity, given by
'r(t) = G(t - t1)Ay, + G(t -t 2 )Ay 2 + ... (4)
As we increase the number of steps, we may take the limit of the summation:
yy t
A~t) = Z:H(t - tn)Arn -4 ZH(t - t')dy~t') (5)
0 0
Then the corresponding stress limit is:
r(t) = Z G(t - tn)Ayn - JG(t - t')dy(t')
0 0
This can also be written as
.t dyI(t)= G(t - t') dt'
0 dt'
(6)
(7)
or
(8)T(t ) = G(t -t')(t' )dt'
One may then apply a sinusoidal shear strain (or alternatively, the same result could be derived
by applying a sinusoidal shear stress):
r= y0oei' (9)
Then:
= idoe'oex"
Thus, substituting (10) into (8), the resulting equation is:
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(10)
zoe'" = icoy0 I G(t - t')e'" dt' (11)
0
We may define a complex modulus G* as being
G* - O ia G(t -t')e-' dt' (12)
Yo 0
Then, changing variables with t- t' s, we finally arrive at
G*= G(s)e~"Ods (13)
0
G* may be broken into real and imaginary parts, which represent the storage and loss modulus.
G* = G'+iG"= w G(s)sin(ws)ds+ if G(s)cos(js)ds (14)
0 0
The significance of the storage and loss modulus is clear when the stress and strain
profiles of a sheared material are plotted together. The strain response will lag behind the shear
by a phase shift 5 if a material has a viscous component. This may be calculated by
tan()= - (15)
G'
For an elastic solid, there should be no phase shift, and so G" should be 0. For a viscous fluid,
the maximum phase shift is 5= )T/2, in which case G' must be 0. Hence the storage modulus
represents elastic energy while the loss modulus represents viscous dissipation.
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2.2 Materials and Methods
All chemicals were used as received. RADA16-II ogliopeptide, biotinylated RADA16-II
(Biotin-GGGGGG-RARADADARARADADA-CNH 2), abbreviated in this document as b-
RADA16-II, and fluoresceinated KFE8 (F-KFFEFKFE-CNH2) abbreviated in this document as
f-KFE8, was purchased from SynPep Corp., Dublin, CA. Phosphate Buffer Saline (PBS) was
purchased from Sigma-Aldrich, St. Louis, MO. Streptavidin was obtained from Molecular
Probes, Eugene, OR. Precision washers were machined in the Central Machine Shop, MIT, with
heights of 0.9 mm, inner diameters of 8.0 mm and outer diameters of 9.0 mm.
Approximately 100 mg of RADA16-II peptide powder was weighed in a 15 mL
Eppendorf tube and mixed with 10 mL of ultra-filtered water to a concentration of 10 mg/mL
(1% concentration by weight). The solution was vortexed at 3200 rpm in a VWR Signature Mini
Vortexor (West Chester, PA) for one minute and sonicated in a jewelry sonicator for 30 minutes.
This stock solution was then stored in 500 pl aliquots in sterile Eppendorf tubes and wrapped in
parafilm to prevent evaporation. Similarly, a 10 mg/mL stock solution of 10 mg of 100% b-
RADA16-II was prepared following the same procedure.
The stock solutions were diluted if necessary to concentrations of 5, 2 and 1 mg/mL by
mixing the appropriate amount of peptide solution with ultra-filtered water. In addition, 1% and
0.1% biotinylated peptide solutions were created by mixing together RADA16-II and b-
RADA1611, both at the same weight concentration, and sonicating the resulting solution in a
small VWR sonicator for 10 minutes at 50 Watts
Streptavidin powder (52.8 kilodalton molecular weight) was stored at -20'C and mixed
immediately with PBS before use to minimize variability and because reconstituted solutions
require the addition of sodium azide or thimerosol to remain stable during long periods of
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storage. Typical concentrations ranged from I mg/mL to 0.1 mg/mL; each milligram of
streptavidin could bind 14 pig of biotin. As there is 1 ptg of biotin in 100 pIL of a 1%, 10 mg/mL
b-RADA16-II solution, we typically used 100 /L of a 1 mg/mL streptavidin solution (enough to
bind 1.4 pig of biotin) to ensure an excess of streptavidin.
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2.3 Caplan Procedure
The Caplan procedure for characterizing the rheology of gels was developed by Caplan
(2000) and modified for these experiments. 30 mL of peptide solution was pipetted onto the
base plate of an AR-1000 or AR-2000 model rheometer (TA Instruments, Eugene Delaware) and
a 2 cm diameter, 18 degree stainless steel cone with truncation of 9 mm was lowered into the
solution. After removal of excess solution, PBS was gently. "dotted" around the perimeter of the
cone using a micropipette, being careful not to disturb the solution, until the PBS fully
surrounded the peptide. 150 mL PBS was also "dotted" onto the plate and a solvent trap lowered
around the area to create a seal that prevented evaporation.
However, this method required up to fifteen hours to allow complete gelation because of
the size of the cone. A diffusion time of approximately 10.7 hours was estimated using the first-
S2
order approximation (derived from Fick's second law) that t = - where x is the length (in this
2D
case, the cone radius of 1 cm) and D is the diffusion coefficient, which for sodium in water is
1.3 x 109 m 2s-'. The long diffusion time was deemed impractical for cross-linking experiments
given that the cross-linker also needed to be added and allowed to diffuse through the gel.
Therefore, a new method was needed to test the efficacy of cross-linkers.
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2.4 New Procedure
Initial results from the cone-and-plate rheometer showed little difference in modulus
from the addition of streptavidin. We theorized that the streptavidin may have bound to the
peptide on the outer perimeter of the gel and might be preventing further diffusion. In addition,
the geometry of the fixed cone made it difficult to wash excess streptavidin out of the peptide.
Thus it was also desirable to create a method that could allow easy washing of the peptide.
Finally, our criteria included low preparation time, the capability of creating many gels from the
same batch of peptide solution and at the same time point, and the ability to test many samples at
once.
Both cones and parallel plates can be used to shear the peptide; the advantage of using a
cone is that the shear remains constant throughout the sample. It is also possible to use a parallel
plate, which requires calculating the response of the sample to linearly increasing shear along the
radius. However, the diffusion time for either fixture depends on the length scale, and the
smallest cone has a radius of 1 cm. Therefore, in order to speed up the test, we chose to use an
8 mm diameter parallel plate instead of the 2 cm cone. This reduced the diffusion time
significantly from 10.7 hours to 1.71 hours.
The procedure we developed allowed for all of these criteria. A porous membrane was
pre-wetted by placing it in a petrie dish atop a paper towel that was soaked with PBS. 30pL
peptide solution was pipetted into a washer that was placed onto the center of the membrane (see
Figure 2-1); due to surface tension, some peptide formed a dome above the 900 Jim height of the
washer. Excess PBS was pipetted on the paper towel and membrane, and after five minutes,
30 mL PBS was carefully pipetted around the edge of the washer to allow diffusion through the
top of the gel. The petrie dish was covered and sealed in paraffin wax for at least one hour.
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After one hour, the membrane and washer were lifted off the paper towel onto the
rheometer plate (Figure 2-2). The excess gel was sliced off using a razor blade (Figure 2-3), the
washer was removed, and the parallel plate lowered to 95% of the original height to ensure that
there was full contact between the peptide surface and the plate (Figure 2-4). The sample was
allowed to equilibrate for one minute before running the test.
Figure 2-1. Pipetting of peptide solution into washers
Figure 2-3. Shearing off of excess gelled peptide
Figure 2-2. Membrane and washer on plate
Figure 2-4. Gel in place on rheometer
For the cross-linking experiments, the streptavidinated PBS was added to the paper towel and on
top of the gel after the one hour time point. The petrie dish was then re-covered and re-sealed for
two hours, then the sample removed and tested.
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2.5 Results
2.5.1 Characterization of RADA16-II
The new rheometry method described in the previous section made it possible to obtain a
gellation timecourse from the same batch of peptide solution. The mean values of five
timecourses are plotted in Graph 2-1. The graph shows that the peptide modulus continues to
change significantly up to and even after the 3-hour time point, but then began to level off. It
was therefore decided that the 24-hour timepoint would be used for characterization.
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Graph 2-1. RADA16-II moduli timecourse. Mean value of five RADA16-II timecourses plotted
with 95% confidence intervals
At the 24-hour timepoint, the new method gave highly reproducible moduli for 10
mg/mL solutions of RADA16-II peptide. Much to our surprise, the moduli were consistently
different for two different Synpep orders of peptide. In peptide from the first Synpep order, the
mean value of the storage modulus G' was found to be 11.17 kPa, while for the second, the mean
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value of G' was 5.53 kPa. The difference in moduli was qualitatively verified in cell experiments
(A.L. Sieminski, personal communication, May 2, 1003) where cells behaved differently when
seeded in peptide gels made from different Synpep order.
The following tables summarize the results:
Modulus
G'
G"
Number of
Samples (n)
9
9
Mean (ji) +/- 95% Standard
confidence Deviation (a)
11.17 +/- 0.83 1.27
0.85 +/- 0.15 0.23
Standard Error
(o/')
0.42
0.08
Table 2-1. Moduli (kPa) of RADA16-I1, Synpep Order 1
Modulus Number of Mean (A) +/- 95% Standard Standard Error
Samples (n) confidence Deviation (a) ( y/4)
G' 12 5.53 +/-0.83 1.46 0.42
G" 12 0.51 +/- 0.09 0.16 0.05
Table 2-2. Moduli (kPa) of RADA16-II, Synpep Order 2
The mean values of the moduli (plotted in Graphs 2-2 and 2-3 with 95% confidence
intervals) demonstrate very little frequency dependence. This is consistent with prior
observations of by Caplan (2002) of peptide gels including KIE12 and KVE12.
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Graph 2-2. Moduli (kPa) vs. Frequency (rad/sec) for RADA16-II (Synpep Order 1)
plotted with 95% confidence intervals.
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Graph 2-3. Moduli (kPa) vs. Frequency (rad/sec) for RADA16-II (Synpep Order 2)
plotted with 95% confidence intervals.
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2.5.2 Characterization of biotinylated RADA16-II
The 1% biotinylated, l0mg/mL RADA16-II (hereafter referred to as b-RADA16-II) was
found to have moduli that were slightly higher than the RADA16-II (Table 2-3), but not
significantly so. Given the similarity of the moduli, the addition of the biotinlyated peptide
seems to have had little effect on the structure of the gelled peptide. Images obtained by atomic
force microscopy (AFM) by Jeong (2004) confirm that in solution, b-RADA16-II forms filament
structures similar to non-biotinylated RADA16-I. It also exhibited little frequency independence
(Graph 2- 4).
Modulus Number of Mean (p) +/- 95% Standard Standard Error
Samples (n) confidence Deviation (a) ( O-/4)
G' 5 11.83 +/- 1.40 1.60 0.71
G" 5 0.87 +/- 0.08 0.10 0.04
Table 2-3. Biotinylated-RADA16-II Moduli (kPa)
100
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Graph 2-4: Moduli (kPa) vs. Freqeuncy (rad/sec) for Biotinylated-RADA16-II
plotted with 95% confidence intervals.
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2.5.3 Addition of Streptavidin
The addition of streptavidin was predicted to strengthen the gel by specifically cross-
linking the biotinylated peptide, but this does not appear to have occurred. For the biotinylated
peptide, adding streptavidin slightly decreased the mean value of G' from 11.83 to 11.41 KPa,
while increasing the value of G" from 0.87 to 0.95 KPa. The non-biotinylated peptide had an
even more unpredictable response: the mean G' value significantly decreased from 11.17 to 9.64
KPa, with a wide
Modulus
G'
G"
Table 2-4
Modulus
G'
G"
T
Modulus
G'
deviation (Table 2-4, with more details in Tables 2-5
RADA16-II RADA16-II b-RADA16-II
(control) (streptavidin) (control)
11.17 +/- 0.83 9.64 +/- 3.70 11.83 +/- 1.40
0.85 +/- 0.15 0.75+/- 0.22 0.87 +/- 0.08
Summary of Streptavidin Experiments: Mean moduli values (
Number of Mean (p) +/- 95% Standard
Samples (n) confidence Deviation (a)
5 11.41 +/- 0.57 1.89
5 0.95 +/- 0.08 0.10
able 2-5: Moduli (kPa) of Biotinylated-RADA16-II with added
Number of Mean (pi) +/- 95% Standard
Samples (n) confidence Deviation (a)
6 9.64 +/- 3.70 3.38
and 2-6).
b-RADA16-II
(streptavidin)
11.41 +/- 0.57
0.95 +/- 0.08
kPa) for all peptides
Standard Error
(c/V )
0.84
0.04
Streptavidin
Standard Error
(Or/- )
1.38
"l6 0.75+/- 0.22 0.27 0.11
Table 2-6: Moduli (kPa) of RADA16-II with added Streptavidin
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2.6 Discussion
Explanations for these results will depend on obtaining concrete evidence that the
streptavidin does in fact bind to the peptide filaments. AFM work by Jeong (2004) is
inconclusive; the number of b-RADA16-II filaments that bundle or overlap appears to be similar
compared with the RADA16-II. Given the strength of the attraction between streptavidin and
biotin, one would have expected an increase in the number of cross-links. However, AFM
images also suggest that the streptavidin has bound along both RADA16-II and b-RADA16-II
filaments, but the resolution is not high enough to determine whether the binding sites coincide
with where the filaments overlap.
M.R. Davis in 2003 (personal communication, February 14, 2003) also was able to
demonstrate qualitatively that radioactive streptavidin 35 (S-35) bound to the filaments. It is not
possible from this assay to tell if the binding was specific or non-specific, but we can conclude
that the streptavidin does interact with the filaments.
There are three possible explanations that take into consideration the AFM, S-35 and
rheometry results:
1) The streptavidin binds non-specifically, a weaker interaction compared to the actin-
biotin interaction. This is likely because it appears to bind to the RADA16-II. Thus
the addition does little to increase the moduli. This may mean that the biotin is not
accessible to the streptavidin.
2) The streptavidin binds specifically at the sites and strengthens the interactions at those
sites However, the strength of the peptide may be determined more by the strength of
the individual filaments rather than the strength of the cross-linking interaction at the
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cross-links. If this is the case, the addition of streptavidin would not increase the
stiffness of the peptide.
3) The peptide may also be maximally cross-linked and the addition of the streptavidin
may not form new junctures. The strength of the peptide may be determined more by
the number of junctures rather than the strength of the cross-linking interaction at
these junctures. Again, the addition of streptavidin also would not increase the
moduli.
It is also apparent from the AFM pictures that the filament networks formed by the
RADA16-II with added streptavidin are less dense than the control. The streptavidin may
interfere with the normal formation of these networks, which would explain the decreased
moduli, although the differences are sufficiently small that they may be due to normal variability
in the measurements. It may be that the interaction between the streptavidin and the RADA16-II
may differ from that with the b-RADA16-II; the presence of the biotin may somehow counteract
the disruptive effects.
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Chapter 3
Fluorescence Microscopy
3.1 Theory
The persistence length of a filament is an indication of filament bending stiffness, which
in turn is a major determinant of gel elastic modulus. For an individual filament, the persistence
length is a characteristic distance over which the tangent vectors along the filament become non-
aligned, that is, where the dot product i(0) 9 t (l) drops below 1 (Figure 3-1). Intuitively, this
correlates with the interpretation of persistence length as a measure of bending stiffness; the
stiffer the material, the greater the order in the filament, and the longer the persistence length.
0(0)
10
0(1) 0(1+Al)
1 l+ Al
Figure 3-1. Tangent angles along filament
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By obtaining a statistically significant number of 'snapshots' of the filament wriggling due to
Brownian motion, it is possible to obtain an average distribution of angles. The point we
randomly select for our origin on each 'snapshot' may not necessarily be at the beginning of
ordered segment, and therefore it is necessary to average the filament lengths.
The distribution of the averages will have a value of 1 at lo (since the tangent vector at lo
is the basis vector and the dot product of a vector with itself is unity). In addition, at higher
values of 1, the distribution becomes randomly distributed and the dot product asymptotically
approaches 0. This distribution can be fitted by a function of the form:
< cos[l(l) - 6(0)] >= Ae-'KM (16)
A and K may be found by considering the thermal equilibrium configurations of a filament,
which are given by the Bolztmann distribution:
(-U(O)/kBT EI eU(O)IkBT
p =-dkBTd&-u~ee 2idkBT
<o[l- 0)]> lBT 2 1 (9
where U(O) -I, the energy in a two-dimensional cantilevered beam. Then the distribution
is given by:
<Cos [0(1)- O(O)]>= EI _e-EI02 121kT co( O(8)
The integral can be solved and we arrive at:
< cos[0()-0(0)] >= e-'T/2EI(19)
for the two-dimensional case, and define persistence length as 1P = EI/IkBT- Then
< cos[9(l) - (0)]>=e 121P (20)
(derivation adapted from Bathe, 2004)
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Therefore, to analyze persistence length, we may observe the Brownian motion of a filament,
capture the frame-by-frame motion, compile a database of filament position from each picture,
and calculate the persistence length by averaging the angles across the filaments:
42
3.2 Materials and Methods
A 10 mg/mL stock solution of non-fluoresceinated KFE8 was prepared following the
procedure described in section 2.1. This solution was then diluted down to 0.1 mg/mL. In
addition, a 1 mg/mL stock solution of f-KFE-8 was prepared and also diluted to 0.1 mg/mL. All
Eppendorf tubes that contained fluorescent peptide solution were wrapped in foil so that
exposure to light was kept at a minimum. The fluoresceinated and non-fluoresceinated solutions
were mixed in another Eppendorf tube to produce a 0.1 mg/mL solution comprised of 50% f-
KFE8. The solution was vortexed for one minute, sonicated for ten minutes, then diluted at a
1:10 ratio to create a solution at a concentration of 0.01 mg/mL. The Eppendorf tube
containging the diluted solution was wrapped in foil and allowed to incubate for 72 hours.
Glass slides were cleaned with a 70% ethanol solution. Narrow, clear channels were
created by sticking two double-sided pieces of tape on the slides an eighth-inch apart and firmly
placing glass cover slips on top (See Figure 3-2).
slide
Cover slip Double-sided tape
Figure 3-2. Slide assembly for viewing solution
10 pL peptide solution was pipetted at the opening of the channel and capillary action
pulled the fluid through the channel. The peptide solution was then imaged using Nikon
TE2000-U oil immersion microscope excited by air-cooled argon-ion laser.
Because the above procedure only worked twice to create peptide filaments, actin
filaments were used to test the code written to analyze the persistence length. The actin was
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polymerized by the following procedure outlined by J. Ferrer (personal communication, January
14, 2005):
Globular actin (G-actin) from rabbit skeletal muscle (AKL-99, >99% pure; Cytoskeleton,
Inc., Denver, CO) was polymerized and labeled with Alexa-Fluor 488 phalloidin (A-
12379; Molecular Probes, Eugene, OR) as follows: actin monomers were diluted in G-
buffer (5 mM Tris-HCI [pH 8.0], 0.2 mM CaC 2, 0.5 mM DTT and 0.2 mM ATP) to a
final concentration of 0.5 mg/mL. The solution was placed on ice for one hour. Then, 2
gL of 6 gM Alexa-Fluor 488 phalloidin (diluted in methanol) was added to an empty 0.5
pL vial and let to dry for one hour at room temperature in dark. A volume of 100 gL of
diluted actin was added to the phalloidin vial, and 10 [LL of F-buffer (50 mM Tris-HCl
[pH 8.0], 20 mM MgCl 2, 1 M KCl, 2 mM CaC 2 , 5 mM ATP, 2 mM DTT) were added to
initiated the polymerization process. This actin solution was left on ice for one hour in
order to reach steady state, where the filaments grew to an average length of -10 gm.
The actin filaments remained functional for at least one week. To observe the actin
filaments using fluorescence microscopy, the actin solution was diluted 1:100 in F-buffer,
to a final concentration of - 5 gg/mL.
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3.3 Preliminary Results
We had limited success in creating and observing filaments from the KFE-8 peptide,
though it was known from AFM experiments that this peptide could form single filaments. The
procedure, as described in Section 2.6, was successful twice but unfortunately could not be
repeated thereafter. However, in the expectation that single filaments could be consistently
induced to form, a Matlab program (Appendix A) was written to analyze the persistence length
of the filaments.
The program first imports the image and allows the user to select points along the
centerline of any number of filaments in an image (Figure 3-3). For each filament, the centerline
is interpolated using cubic splines, and pixels that lie along the spline are selected and reordered
into vectors. The angles along these vectors are calculated, compiled into a matrix and averaged.
Finally, an exponential fit is performed and the persistence length is calculated.
Figure 3-3. Selection of centerline points for actin filaments
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In lieu of a conclusive result for the peptide, the program was used to analyze the
persistence length of actin filaments stabilized with rhodamin phalloidin. Actin polymerization
was performed by J. Ferrer as indicated in Section 2.6. Literature values for stabilized actin
filaments appear to vary widely in range. Gittes et al. (1993) found a range of 17.7 +/- 1.1km
using modal analysis. Kas et al. (1993), however, using a similar modal analysis, found a "wave
vector dependent persistence length" ranging from 0.5 m to 5 gm. Finally, Riveline et al.
(1997) subjected the actin filament to bending through external forces and viscous drag, and
calculated a persistence length of 7.4 +/- 0.2pm. The filaments studied in this experiment were
attached at one end to a bead and allowed to fluctuate in the solution.
We analyzed the angles of 78 different filaments that were at least 2.5 gm in length (see
Appendix A for code). However, as most of the filaments were longer, each "contained"
multiple vectors for analysis. A vector of 51 pixels, for example, contains two vectors of 50
pixels by shifting the starting point of the analysis by one pixel along the filament. Therefore the
program actually averaged the angles of 5,839 vectors. The exponential fit is given in Figure 3-
4. We found that the persistence length is 3.85 m, consistent with Kas's range for rhodamin-
phalloidin-stabilized filaments.
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Persistence Length Exponential Function
* data
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Figure 3-4. Exponential fit of actin filament data
It is hoped that this Matlab program can be used to analyze the persistence length of the peptide
filaments when single filaments can be consistently produced and clear images consistently
obtained.
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Chapter 4
Summary and Future Directions
4.1. Rheometry
The new rheometric procedure is an alternate way to characterize of the moduli of the
peptide gel and its use can be expanded to analyze other viscoelastic solids. More importantly, it
is now possible to reliably analyze the effects of cross-linkers on the properties of the material.
However, the cross-linker we tried-streptavidin-did not have the predicted effect of
strengthening the RADA16-II. We have set forth several theories for the reason, and this
interaction may be studied further to determine the possibilities of this substance for cross-
linking. Preliminary results by M.R. Davis (personal communication, August 13, 2004) imply
that the streptavidin-biotin affinity, when the biotin is linked to the peptide, is not as strong as the
textbook value for the dissociation constant (KD =10-") would suggest. The AFM work carried
out by Jeong (2004) may also be repeated to try to better ascertain the interaction between the
streptavidin and the filaments on the micron scale. But as the AFM procedure requires the
peptide to be studied at very low concentrations, this work is ultimately of limited value in
seeing the variation in gel structure at the concentrations used in cell experiments. Therefore,
electron microscopy might be a better way to study how the addition of cross-linkers affects the
bulk properties of the material.
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It may also be possible to model the interaction between the biotinylated peptide and the
streptavidin to gain insight into molecular mechanics. If we assume that the streptavidin-biotin
bonding occurs, then we have an estimate for bond strength, and this could be used in a more
comprehensive model of gel rheology.
Control of the properties of biomaterials remains an important research area. Other
cross-linkers, both specific and non-specific, may be more successful in controlling the modulus.
The selection of these reagents must be based partly on the interaction between the cross-linkers
and cells; the in vitro and in vivo properties of the biomaterial must remain primary
considerations.
4.2. Fluorescence Microscopy
The persistence length of a single filament may be used to confirm our understanding of
the bulk properties of the material. The first priority is to determine a repeatable procedure for
the creation of the single filaments. In our study, we varied the overall concentration of peptide,
the proportion of peptide with fluorescent markers, and incubation time. It was hoped that a high
initial concentration of peptide would induce nucleation, and dilution and a long incubation
would then allow the formation of long single filaments. This strategy may need to be rethought,
as clearly there are other variables that affect filament formation; it may be necessary to also
control for temperature and other factors.
As the resolution of the microscope and image acquisition system improves, it should be
possible to more accurately characterize the curvatures of the filaments. Currently some regions
along the filament are represented by very few pixels, which creates a bias in the calculation. A
better representation is necessary.
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The current microscope also has some limitations in capturing the images of freely
moving filaments as they quickly move in and out of focus due to Brownian motion. It may be
possible to slow down the movement of the filaments by increasing the viscosity of the solution
by adding glycerin or other buffer that will not disrupt the polymerization. The best images of
the filaments thus far have been those that have been trapped onto the surface of the slide. On
such filaments, it is possible to use Total Internal Reflection Fluorescence (TIRF) microscopy,
where the excitation light is completely reflected back from the surface/solution interface and an
evanescent wave illuminates a region extending approximately 100 nm into the solution,
drastically reducing background fluorescence. Yet the filaments that are stuck on the surface of
the slide may become aligned when pipetted into the slide chamber and do not exhibit the same
degree of fluctuation as filaments in free solution. Therefore it is critical that a system is
developed whereby the filaments may be observed clearly while in solution.
4.3 Conclusion
The results from this research provide a baseline for future characterization of the peptide
biomaterials, and indeed, any other class of viscoelastic biomaterials that may be used for cell
scaffolding. The major accomplishment of this research has been the development of a new
method for rheological studies of the peptide gels. It is hoped that this method will aid in the
discovery of effective cross-linkers that can control the stiffness and other important material
properties of biomaterials.
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Chapter 5
Stem Cell Policy Background
5.1 Introduction
President George W. Bush announced his administration's human embryonic stem cell
(hESC) research policy on August 9, 2001, which limited federal funding for to hESC cell lines
created before 9:00 a.m. that morning. In a nationally televised address, Bush explained that it
would be unethical to use federal money to "cross a fundamental moral line, by providing
taxpayer funding that would sanction or encourage further destruction of human embryos that
have at least the potential for life" but that he would allow funds to be used for research where
"the life and death decision has already been made" (Bush, 2001).
The reaction of the scientific community was mixed. Some researchers had previously
expressed fears that all U.S. federal funding would be cut off (Holland, 2001; Shadid, 2001), and
to them the allowance of some research was seen as a pragmatic compromise. For example,
Timothy McCaffrey, an adult stem cell researcher from George Washington University, was
quoted in the San Francisco Chronicle as saying:
Considering the difficult positions [President Bush] had to weigh, it appears to be quite a
fair decision... Obviously, as a scientist, you want as few restrictions on your work as
possible... But this doesn't disable the field at all. Compared with being unable to use
federal funds, period, for stem cell research, this is a big step forward (qtd. in Hall,
2001).
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Douglas Melton of Harvard University, one of the first American researchers to co-author a
paper on hESC research, appeared to respect the Administration's decision. "The compromise
he's tried to achieve is a laudable one," he told Science Magazine a week after the policy was
announced (Vogel, 2001).
But other researchers were less kind. Several expressed concerns that the quality of the
existing cell lines was questionable and that confining the research to the purportedly existing 70
lines would significantly limit the genetic pool and thereby curtail the potential for cell
transplantation therapy (Sandalow, 2001). Others pointed out that the stem cell lines were
cultured with mouse feeder cells and could be contaminated (Coile and Hall, 2001). To these
scientists, the Bush Administration's policy was frustratingly restrictive.
Underlying these concerns were fears that American scientists would soon be outpaced
by international colleagues who did not face such stringent regulations, and that American
companies would also miss the birth of a new biomedical therapy. These qualms were fueled by
the widely publicized departure of Roger Pedersen, a stem cell researcher at the University of
California, San Francisco, to the University of Cambridge in the United Kingdom. In July 2001,
Pedersen had foreseen the uncertain future of stem cell research in the United States, feeling he
had to choose between "very favorable circumstances and tremendous support [in the United
Kingdom] ... or the prospect of sitting on my hands for the next few years" (Regalado, 2001).
Soon after the Bush speech, Pedersen told the Guardian:
If this opportunity continues to be squandered in the US, I think there are other people
such as myself who would see the balance of opportunity shifting towards the UK...
Academics are pretty fluid in their ability to move around these days, and if the UK
provides the opportunity it could benefit quite substantially. Right now it's at the
academic level, but in the future it could be at an economic level, because I believe a
whole new industry could arise from this technology (Meek, 2001).
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Over the past seven years, the possibility of this "reverse brain drain"-a mass movement
of stem cell scientists from the United States to more permissive nations, or from stringent to
permissive states-has been continuously reported in the mainstream and scientific press. In
addition, the derivation of stem cells from the first cloned human blastocyte by South Korean
scientists in 2004 prompted worries that U.S. scientists were no longer on the cutting edge. "You
are going to start picking up Nature and Science and all the great journals, and you are going to
read about how South Koreans and Chinese and Singaporeans are making advances that the rest
of us can't even study," said Dr. Irving Weissman of Stanford University in an interview with the
Boston Globe (Cook and Allen, 2004).
However, no quantitative data has been presented to demonstrate the validity of these
concerns. To better understand the effects of federal policy, we have compiled a database of
every major non-review (original research) hESC article since the first cell line was derived. By
examining this publication data we seek to demonstrate that because the major foreign groups
that had derived stem cell research before 2001 had an incentive to abide by U.S. policy in order
to receive federal funding, U.S. researchers have not in fact lost ground to their international
colleagues. However we also demonstrate that some of the most interesting new publications are
those funded by private sources and that we may be on the cusp of great change in this field.
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5.2 Stem Cell Background
5.2.1 Scientific Background
Many cells have the ability to differentiate into other cells, but to varying degrees. A
fertilized egg immediately begins dividing and within five days develops into a blastocyte, which
is a ball of approximately 200 cells that has a characteristic outer shell and an attached inner cell
mass. This inner mass contains the totipotent cells known as embryonic stem cells that have the
potential to self-replicate or become any cell in the body. Upon implantation in the uterine wall
on the seventh to ninth day, the stem cells specialize into tissue-specific (called "adult" or
somatic) stem cells that exhibit self-renewal and clonogenicity as well as the potential to become
any cell type that is present in the tissue (National Institutes of Health, 2001). Kidney stem cells
can therefore develop into all cells present in the kidney, skin stem cells into skin; this limited
capacity to differentiate means these tissue stem cells are likely multipotent, not totipotent.
However researchers have also discovered that under certain circumstances, somatic stem cells
may exhibit more plasticity than previously thought; for example, mensenchymal stem cells
found in umbilical cord blood have been coaxed to express neural markers (Ha et al., 2001).
A small number of somatic stem cells have been found in most tissues, but it appears that
most become dormant as the embryo matures and are only activated in the adult in the case of
disease and injury (National Institutes of Health, 2001). Some cells, however, such as the
hematopoietic cells that give rise to blood cells, remain active and continually divide and
replicate (Ogawa, 1993). Bone marrow transplants for leukemia patients are essentially
transplants of these adult hematopoietic cells.
The isolation of stem cell types proceeded in a reverse chronological order to their stage
of development. In 1906, A.A. Maximov, a Russian scientist who worked with lymphocytes,
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proposed a "unitarian hematopoietic theory" in which he outlined his belief that blood cells
differentiated from hematopoietic stem cells (Konstantinov, 2000). But proof of this
extraordinarily prescient theory had to wait until 1961, when Till and McCulloch transplanted
healthy rat bone marrow into irradiated rats incapable of producing blood cells. The spleens of
these rats contained colony-forming units from which adult hematapoietic stem cells were
eventually isolated (Becker, Till & McCulloch, 1963).
Advances in in vitro fertilization provided researchers the necessary abilities and
techniques to isolate mouse embryonic stem cells in 1981. Evans and Kaufman extracted the
inner cell mass of a blastocyte and culturing it on a feeder layer of other murine cells (1981).
Some of the resulting colonies of cells showed a remarkable ability to grow into all three skin
cell types. Primate embryonic stem cells were first cultured in 1995 by Thomson et al. (1995),
and in 1998, Thomson led a U.S.-Israeli team that reported the first derivation of human
embryonic stem cells (Thomson et al., 1998). Groups around the world from Australia to Spain
have since reported successful derivations.
Initially, human embryonic stem cells lost pluripotency without being plated on feeder
cells, and many early lines were plated on murine fibroblasts or other murine cells. However, a
team of researchers from the University of California, San Diego, discovered in early 2005 that
mouse cells had contaminated the HI stem cell line because those cells expressed an
immunogenic non-human sialic acid (Martin et al., 2005). It has long been possible to culture
the hESC on human feeder cells, as researchers have reported in California (Xu et al., 2001),
Singapore (Richards et al., 2002), Sweden (Hovatta et al., 2003), and Israel (Amit et al., 2003),
among others. But it remains that all lines available under the Bush administration policy cannot
be used for cell transplantation.
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Human embryonic stem cells have demonstrated their ability to differentiate into neurons
(Schuldiner et al., 2001), hematopoietic cells (Kaufman et al., 2001), cardiomyoctes (Kehat et
al., 2001), hepatocytes (Rambahtla et al., 2003) and other cells. Researchers have also been able
to derive stem cells from frozen or discarded embryos (Mitalipova et al., 2003). And early in
2004, researchers in South Korea announced the derivation of stem cells from a cloned human
blastocyte (Hwang et al., 2004), the first verified instance of human cloning.
5.2.2 Advantages of embryonic stem cell research
One of the major criticisms of human embryonic stem cell research is that somatic and
umbilical cord blood stem cells also have potential to be used for therapeutic treatment. For
example, to justify his administration's policy, President Bush said that "...many scientists feel
research on [adult and umbilical] stem cells is also promising. Many patients suffering from a
range of diseases are already being helped with treatments developed from adult stem cells"
(Bush 2001).
However, thus far, somatic stem cells appear only capable of limited self-renewal in
culture, which is one of their main drawbacks as a cellular therapy treatment. Further, they are
difficult to isolate as they exist in very small numbers in the tissue; for hematopoietic cells, for
example, the ratio may be 1:15,000 cells in bone marrow, and 1:100,000 in the bloodstream
(National Institutes of Health, 2001). In addition, to be viable, somatic cell therapies would have
to overcome a substantial obstacle: immune rejection. Somatic cell lines taken from deceased
individuals will never be genetically identical and will have the same immunogenic problems as
organ transplants. However, as umbilical cord blood stem cells appear to have some similar
properties as embryonic stem cells, private cord blood banks have been established in the U.S.
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and U.K. so that the cells may be available if individuals require them in the future (Abelson,
2004; Wheelwright, 2004).
When confronted with a new technology, policy makers must understand the scientific
detail but also the social and political climate in which laws are promulgated. The next section
will explore the ethical climate in detail.
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5.3 Ethical perspectives
President Bush's 2001 policy announcement included this extraordinary parallelism:
...one researcher told me he believes this five-day-old cluster of cells is not an embryo, not
yet an individual, but a pre-embryo. He argued that it has the potential for life, but it is not
a life because it cannot develop on its own.
An ethicist dismissed that as a callous attempt at rationalization. Make no mistake, he told
me, that cluster of cells is the same way you and I, and all the rest of us, started our lives.
One goes with a heavy heart if we use these, he said, because we are dealing with the seeds
of the next generation. (Bush, 2001) (see Appendix B for complete text).
The parallelism may be a rhetorical device, but by framing the issue as "science vs. ethics" and
coming down squarely on the side of "ethics," President Bush attempted to claim the moral high
ground. And by citing prayer and faith in his speech four times, President Bush also appeared to
claim a religious mandate.
However, the ethics of stem cell research are considerably more complex than President
Bush would seem to suggest. At the outset, it seems unwise to aggregate all ethical and religious
beliefs into one monolithic entity when even among Christian denominations, there are
significant differences in opinion. A 2003 Gallup poll found that 67% of people who seldom or
never attend church find stem cell research morally acceptable, but only 38% of those who attend
church weekly agree (Gallup, 2003). While the difference is significant, the fact that nearly 40%
of churchgoers support the research makes a solely religious framing of this debate untenable.
In addition, the positions of centralized religious groups with definable leadership are
quite dissimilar on this issue. For example the Presbyterian Church (USA) is in favor of hESC
research because:
... [i]ndications are that human embryonic stem cell research has the potential to lead to
lifesaving breakthroughs in major diseases. Currently, this knowledge cannot be obtained
from cells derived from other sources such as adult stem cells and cadaveric fetal tissue.
Prohibition of the derivation of stem cells from embryos would elevate the showing of
respect to human embryos above that of helping persons whose pain and suffering might
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be alleviated... Therefore, the 213th General Assembly (2001) of the Presbyterian
Church (U.S.A.), affirms the use of fetal tissue and embryonic tissue for vital research
(Presbyterian Church, 2001)
It must be noted that the Presbyterian Church is one of few religious denominations that supports
a woman's right to choose an abortion.
On the other hand, the Catholic Church is strongly against both abortion and embryonic
stem cell research. The late Pope John Paul II outlined his views on embryonic cloning in an
address a conference on transplantation therapies in Rome in 2000:
... [M]ethods that fail to respect the dignity and value of the person must always be
avoided. I am thinking in particular of attempts at human cloning with a view to
obtaining organs for transplants: these techniques, insofar as they involve the
manipulation and destruction of human embryos, are not morally acceptable, even when
their proposed goal is good in itself. Science itself points to other forms of therapeutic
intervention which would not involve cloning or the use of embryonic cells, but rather
would make use of stem cells taken from adults. This is the direction that research must
follow if it wishes to respect the dignity of each and every human being, even at the
embryonic stage. (John Paul II, 2001)
These position papers outline two basic debates: first, the status of the embryo and
whether it should be accorded human rights, and second, the conflict between utilitarianism and
individualism. A third common debate about the ethics of new technologies considers the
difference between "natural" and "unnatural" actions, which is related to risk aversion and
precaution. Religious beliefs may influence positions on these debates, but none are wholly and
exclusively religious in origin.
5.3.1 The status of the embryo
Equality of rights is one of the basic tenets of modem democratic governments. In the
United States, the ideal has been near-mythologized in the Declaration of Independence: "We
hold these truths to be self-evident, that all men are created equal, that they are endowed by their
59
Creator with certain unalienable Rights, that among these are Life, Liberty and the pursuit of
Happiness" (Declaration of Independence, 1776). The writers of this document justified equality
by invoking natural law, as have many philosophers from Aristotle onwards, and since
Enlightenment times, it has also been justified on rational principles. Given the dominance of
democracy in modem history, this ideal may be implicitly believed in many societies.
The debate over the status of the embryo may therefore be framed as a debate on the
context of the universality of rights. Those against using embryonic research may believe that
moral principles should be applicable to all similar situations, and if killing an innocent person is
wrong, then killing an embryo must also be wrong. Those in favor of embryonic research may
believe that the embryos do not exhibit any characteristics of personhood, and therefore, the
conventional rights we accord human beings need not be extended.
5.3.1.1 Religious perspectives
Some religions, such as Buddhism and Hinduism, do not have a central authority who
speaks for the entire community, and it is difficult to categorically define the positions of the
believers. On the other hand, few religions are as centralized as the Catholic Church, which has
a leadership that promulgates the church's opinions on new and controversial issues. The
Catholic believe in the existence of a soul, and that when a soul enters a body it confers
personhood: "[i]n procreation therefore, through the communication of life from parents to
child, God's own image and likeness is transmitted, thanks to the creation of the immortal soul"
(John Paul II, 1995). For this denomination, stem cell research is clearly immoral.
Islam and Judaism are somewhere in between these extremes; they are much less
centralized than Catholicism and do not have one sole leader, but also have established sacred
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texts that can be interpreted by scholars. These texts are a foundation for religious law. But on
the status of the embryo, the Qu'ran is ambiguous:
And certainly We created man of an extract of clay, Then We made him a small seed in a
firm resting-place, then We made the seed a clot, then We made the clot a lump of flesh,
then We made (in) the lump of flesh bones, then We clothed the bones with flesh, then
We caused it to grow into another creation (Surat 23:14).
Similarly, the Talmud, a collection of Jewish rabbinical laws, traditions and teachings does not
require a women go through the ritual of cleansing if she miscarries before 40 days for males and
80 days for females (Niddah: 30 (Mishnah)), but this only implies the status of the embryo.
Yet some Muslim philosophers put the time of ensoulment at 40 to 120 days (Lampman,
2001), and at least the Reform Jews have cautiously endorsed hESC research (Niebuhr, 2004).
Such beliefs are personal, unarguable, and even, as the Catholic Church admits, empirically
unsolvable (Secretariat of State, 2004).
5.3.1.2 Kant's categorical imperative
Immanuel Kant (1724-1804) was one of the first modem philosophers to justify ethical
actions by their universalizability; his categorical imperative requires that we "act only according
to a maxim by which you can at the same time will that it should become a universal law" (Kant,
1800)--that is, any rational being would act the same way under all similar hypothetical
situations. But because even rational beings act because they wish to bring about some end, to
base a philosophy on subjective desires and incentives would not make them valid universally.
Kant therefore proposes as a basis for practical law, that rational natures are "ends" in
themselves, and thus we should "act in such a way that you treat humanity, whether in your own
person or in the person of another, always at the same time as an end and never simply as a
means" (Kant, 1800). Thus we must put ourselves in the position of each affected party, which
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leads to the requirement of human dignity: if we expect it for ourselves, we must grant it to
others.
Thus some ethicists invoke Kantian philosophy as a way to demonstrate the immorality
of hESC research:
The creation of human clones solely for spare cell lines would, from a philosophical point
of view, be in obvious contradiction to the principle expressed by Emmanuel Kant: that
of human dignity. This principle demands that an individual--and I would extend this to
read human life--should never be thought of as a means, but always also as an end.
Creating human life for the sole purpose of preparing therapeutic material would clearly
not be for the dignity of the life created (Kahn, 1997).
Yet even if one accepts the tenet of universality, one must nevertheless decide if it should
apply to embryos. Kant's categorical imperative, despite its attempts at objectivity, still depends
on the demarcation of categories, and this is very subjective indeed. Categories are not defined a
priori and appear to change over time-for example, blacks were not considered to be fully
human by whites for much of modem history. Thus even practical foundations of justice based
on Kant, such as John Rawl's recommendation of "equal basic liberties compatible with a similar
scheme for others" (Rawls, 1999) cannot be applied until it is decided if the embryo has a right to
life.
One argument for the rights of an embryo stems from what might be called the
potentiality argument. All embryos have the potential to become specific, individual humans,
and presumably like other humans, they would wish for existence. Therefore, if we do not
condone the killing of innocent adults or children, and as the difference between an embryo one
minute before birth and a baby one minute after is negligible, we must conclude that if we are
against murder and infanticide, we should also be against any act that harms an embryo,
including abortion or hESC research. As one anti-abortion advocate states,
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The future of a standard fetus includes a set of experiences, projects, activities, and such
which are identical with the futures of adult human beings and are identical with the
futures of young children. Since the reason that is sufficient to explain why it is wrong to
kill human beings after the time of birth is a reason that also applies to fetuses, it follows
that abortion is prima facie seriously morally wrong (Marquis, 1989).
However, a five-day-old cluster of cells bears little resemblance to a sentient adult--"it
lacks any of the anatomical features of a human being, including, most importantly, a brain and
nervous system. Hence it could not possibly suffer in any way from the experimentation"
(Singer, 1994). In addition, we cannot know if embryos-who cannot think or speak for
themselves-indeed wish existence, and it is irrational to presume this without justification.
Further, one could argue that the potentiality argument is a case of reductio al absurdum. The
union of every egg and sperm has the potential to become an individual being, and if one strictly
applies universality, one must consider the wishes of all the hypothetical children that could
result from every possible union. Then one would "derive not only a duty not to abort, but also a
duty not to abstain from procreation" (Hare, 1975). And this is absurd to some because we do
not hold people accountable for deciding not to have children; we have no duty to bring all
potential beings into the world.
Given the lack of consensus over basic philosophical axioms and categories, it is likely
that the debate over the status of the embryo will continue to frame the issue of stem cell
research, as it has for abortion, for years to come.
5.3.2 Utilitarianism vs. individualism
Even if Kant's practical law is followed to the letter, there will be situations in which two
people's rights to life come into conflict. If two people are on a transplant list, and one will get
the organ and the other will die, whom should we choose? Or, strict Kantians would say that if a
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woman aborts a fetus because her life would be better without it, she is treating the fetus as a
means, not an end. But under the same logic, an embryo uses a woman's uterus as a means to
becoming born, and this should be considered equally immoral. Rawls considered this problem
of prioritization and explained that we should rely on the principle that "economic and social
inequalities are to be judged in terms of the long-run expectations of the least advantaged social
group" (Rawls, 1999). The lack of justification for this kind of principle or any like it, however,
is unlikely to convince any who think differently.
John Stewart Mill (1806-1873) attempted to provide another problematic rule for
morality based on consequences. He proposed a "greatest happiness" principle in which "actions
are right in proportion as they tend to promote happiness; wrong as they tend to produce the
reverse of happiness. By happiness is intended pleasure and the absence of pain; by
unhappiness, pain and the privation of pleasure" (Mill, 1861). But the main impracticality of
utilitarianism is that measuring happiness is not a trivial task. Here the sentience of the embryo
is a key issue. If an embryo is not sentient, it feels neither happiness nor pain; it is a neutral
being and its death is neither good nor bad except as measured in the happiness or pain of those
affected by its death.
Therefore, utilitarianism is a common philosophy used to justify especially the derivation
of stem cells from human embryos that were created but not used for reproductive purposes. As
these supernumerary embryos sit indefinitely in cold storage until the parents decide to destroy
them, many, including Senator Bill Frist (R-Tenn) and conservative commentator and President's
Council on Bioethics panel member Charles Krauthammer (Krauthammer, 2001), argue that the
potential benefits to the human community outweigh the costs.
64
Opponents of utilitarianism, however, believe that certain actions are simply wrong and
that one cannot sacrifice an individual for the sake of the greater good. These arguments are
demonstrated in hypothetical situations such as one where the entire world could become
transformed into a paradise only if a child was tortured. That is, to some, morality is not based
on the consequences of an action, but on inviolable principles or rules of ethics such as ones
outlined in the previous section. And if one believes de facto that killing an embryo is wrong
based on a different set of moral criteria, it does not matter how much good embryonic research
could achieve.
5.3.3 Precaution and progress
Many critics of new technologies discuss a "slippery slope" whereby the advances of
science may change our relationship with the natural world for the worse. Opponents of in vitro
fertilization predicted "horrendous possibilities for human manipulation" (Tighe, 1994) such as
genetic engineering, human-animal chimeras, sex selection, and second-class clones used for
spare body parts. President Bush used this logic in his August 2001 speech, where he said that:
... [e]mbryonic stem cell research is at the leading edge of a series of moral hazards. The
initial stein cell researcher was at first reluctant to begin his research, fearing it might be
used for human cloning. Scientists have already cloned a sheep. Researchers are telling
us the next step could be to clone human beings to create individual designer stem cells,
essentially to grow another you, to be available in case you need another heart or lung or
liver (Bush, 2001).
It must be noted that "grow[ing] another you" to describe the creation of artificial organs is a
gross misstatement. Nevertheless, the "slippery slope" remains a persistent argument, and its
advocates urge precaution in interfering with natural processes. In this way, they drawn on
Aristotelian arguments that each thing is for a purpose, that "whenever a sequence has an end,
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the earlier action and the next in order are done for the end... what is natural, therefore, is for
something" (Aristotle, Physics).
Advocates of new technologies argue that nature has no teleological destiny or foresight,
and even if it did, one could not say that everything that occurs naturally is good. The natural
world is one of influenza epidemics and bubonic plagues, earthquakes and hurricanes, suffering
and destruction. Thus there is nothing inherently wrong with humans intervening with nature.
Further, the slippery slope presumes a single, absolute scale of morality. However, society has
adjusted to many formerly controversial treatments; blood transfusions and vaccinations were
considered to be unnatural in the 1800s but are commonplace today. In more recent years, in
vitro fertilization, introduced in the 1970s, has ceased to be controversial for many.
One's preference for either progress or precaution may depend on one's level of risk-
aversion. The slippery slope argument is actually a reformulation of a common policy
consideration of Type I and Type II errors. In statistics, a Type I error is a false positive. For
example, a test may show that a drug is safe when it is not. The costs of such an error could be
high; many people could be endangered if the drug is put on the market. On the other hand,
Type II errors are false negatives where test judges something to be unsafe when it is safe. But
again, the costs of the error could be high; if a safe drug is kept off the market on the basis of an
invalid test, users who could have benefited must do without.
When faced with the possibility widespread or irreversible negative consequences, the
"precautionary principle" may be invoked by the risk-averse. This principle favors Type I errors
over Type II errors. It is presumed that however safe a new technology has been shown to be,
there is always the possibility that something was missed. Then the risks should not be borne
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when nature could take its gradual course. Furthermore, none of the affected people are any
worse off than if the technology was not available.
For hESC research, however, it is difficult to invoke the precautionary principle. The
uncertainty of this technology is related not to a physical or testable system, but to "moral
hazard," which is impossible to quantify objectively. If we cannot even agree on an absolute
scale of hazard, it is unlikely that arguments based on the unnaturalness of new research will be
convincing.
Ultimately, the debate on the ethics of stem cell research will never be settled. However,
some views may gain societal acceptance through codification into law. Policy does not depend
on an absolute debate about ethics, but rather the efficacy of the proponents to advance their
agendas in political institutions. The next chapter analyzes the political systems in the United
States and other nations to gain insight into the different approaches to hESC research.
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Chapter 6
Policy Analysis
6.1 U.S. human embryonic stem cell policy
The federal government has never banned embryonic research, but since 1979 it has
restricted the use of federal funding. Federal funds are administered through the National
Institutes of Health, the budget of which is allocated as part of the Department of Health and
Human Services (HSS), formerly the Department of Health, Education and Welfare (HEW).
Legislation passed in 1975 in response to the emergence of in vitro fertilization (IVF) research
required all federal funding to be approved by a HEW Ethics Advisory Board ("Protection of
Human Subjects", 1975). However, this board was disbanded in 1979 after recommending that
IVF research was ethical (National Commission for the Protection of Human Subjects, 1979) and
from then on, no other boards were chartered. And as the legislation remained in place, no
embryonic research could be federally funded.
The Reagan administration passed a temporary moratorium on federal funding for all
fetal tissue research in 1988, which was extended through the first Bush administration (Fetal
Tissue Transplantation, 1988) and which President Clinton lifted in 1993 (Federal Funding for
Fetal Transplantation Research, 1993). Nonetheless, in 1996 (and every year thereafter),
Congress passed and President Clinton signed the "Dickey Amendment," a rider introduced by
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Representative Jay Dickey (R-Arkansas) on the HHS appropriations bill that was interpreted as
preventing federal funds from being used on any embryonic research. The amendment read:
None of the funds made available in this Act may be used for--
(1) the creation of a human embryo or embryos for research purposes OR
(2) research in which a human embryo or embryos are destroyed, discarded, or
knowingly subjected to risk of injury or death greater than that allowed for
research on fetuses in utero under 45 CFR 46.208(a)(2) and section 498(b) of
the Public Health Service Act (42 U.S.C. 289g(b)) (Budget of the United
States Government, 1996).
After Thomson et al were able to extract the first stem cell lines from human blastocytes
in 1998, the National Bioethics Advisory Commission recommended to President Clinton in
2000 that the Dickey Amendment did not apply to research on cell lines already derived with
private funding. They pointed out that according to the NIH Revitalization Act (1993), research
on fetuses was permitted if it "pose[d] no added risk of suffering, injury, or death to the fetus and
the purpose of the research or experimentation is the development of important biomedical
knowledge which cannot be obtained by other means." Thus because federal funding for
research on already-created cell lines posed no additional risk of death to the embryo, it was
legally valid to allow it.
However, when the second President Bush took office in 2001, he immediately restored
the moratorium on federal funding and appointed the President's Council for Bioethics to advise
him on the divisive issue (Bush, 2001). Through the spring and summer of 2001, various policy
makers gave suggestions to the President, including prominent Republicans, who gave
conflicting advice. Senator Bill Frist (R-Tennessee), the Senate's only doctor and a close advisor
of President Bush, suggested that would allow federal funding for frozen embryos that would be
destroyed anyway, which was in line with NBAC's original recommendations (Bayot, 2001).
However, House leadership including Representatives Dick Armey (R-Texas) and Tom DeLay
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(R-Texas) spoke out publicly about a complete ban on federal funding for both derivation and
use of embryonic stem cells:
The federal government cannot morally look the other way with respect to the destruction
of human embryos, then accept and pay for extracted stem cells for the purpose of
medical research... It is not 'pro-life' to rely on an industry of death, even if the intention
is to find cures for diseases. We can find cures with life-affirming, not life-destroying,
methods that are becoming more promising with each passing day (qtd. in Wolffe, 2001).
Finally, President Bush announced his compromise policy on August 9, 2001 that restricted the
use of federal funds to already-derived stem lines (Bush, 2001).
U.S. lawmakers have thus far been unable to pass any legislation to allow or ban
therapeutic and reproductive cloning. Because some legislators favor a ban on all cloning and
others favor a partial ban that allows cloning for research to continue, several bills have stalled in
the Senate since 2002 (Stolberg, 2002; Epstein, 2004). However, various ethical panels have
attempted to set guidelines for stem cell research in recent years, ranging from the President's
Council for Bioethics (1999) to the National Academy of Sciences (2005). The possibility of
widespread voluntary adoption rests on the reputation of the institutions, but without the force of
law behind them, these guidelines may remain mere suggestions.
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6.2 Comparative policy
Although the United States does not currently permit federal funding for the derivation
and use of new stem cell lines, there is no specific federal legislation that governs human
embryonic stem cell research or cloning. Thus the U.S. currently allows research more freedom
than many other countries.
Several countries have banned all hESC research, such as Poland (Barton, 2004), while
Germany does not allow the derivation of new lines but permits the importation of hESC derived
elsewhere that meet strict ethical conditions (Campbell, 2005). Most other countries allow the
derivation of hESC from "supernumerary" embryos originally derived for fertility treatments but
ban every other type of procedure, including somatic cell nuclear transfer (SCNT) for therapeutic
purposes. Finally, some countries have legislated the allowance of SCNT for therapeutic
research but ban reproductive cloning. Other countries have no specific legislation on hESC but
have legislation about the rights of the embryo or restrictions on fetal tissue that amount to a
complete ban. It is presumed that where no specific legislation has been passed, a country allows
the practice. Table 6-1 gives a summary of the laws in several countries.
Policy Country
Complete or de facto ban on research Austria, Ireland, Italy, Luxembourg, Peru, Poland,
Portugal, Tunisia
Allowance of research on only imported hESC Germany
Allowance of derivation of hESC only if Australia, Brazil, Czech Republic, Denmark, Estonia,
embryos were supernumerary Finland, France, Greece, Hungary, Iceland, India, Iran,
Slovenia, Spain, Switzerland, Taiwan
Allowance of derivation of hESC from Sweden, UK
embryos created specifically for research
Allowance of hESC from somatic nuclear cell Belgium, India, Israel, Japan, the Netherlands,
transfer (therapeutic cloning) Singapore, South Korea, Sweden, UK
No federal legislation or de facto ban United States
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Table 6-1. Summary of hESC policies of selected countries
(Hoffmann, 2005; International Society for Stem Cell Research, 2003)
The European Union allows member states to set their own policies on stem cell research,
but currently there is no EU-level funding for hESC research. Recently despite a budget
proposal to allocate C200m for stem cell research over a four year funding cycle ending in 2007
(Minder, 2003), a moratorium on EU funding was upheld in part due to the objections of
Germany, Austria and Italy (Black, 2003).
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6.3 Policy analysis
A country's lack of legislation may be interpreted as both liberal and conservative. It may
currently allow practices that others do not allow, but there is no guarantee in the long-term;
certain procedures could be banned at any time. The difference in policies depends both on the
underlying culture and ethical views of the population as well as its political processes. Public
opinion in historically Catholic countries is against hESC research, to the point where in Ireland,
the "unborn" is given the same rights as its mother (Colbert, 2003). Some countries also may
have historical reasons for opposing the research: in Germany, for example, guilt about human
experimentation under the National Socialist regime has turned public opinion away from any
human embryonic research (Campbell, 2005).
But underlying culture and public opinion can only explain so much. A July 2001 poll by
Roy Morgan International, an Australian public opinion polling firm, found that 40% of
Americans supported therapeutic cloning, with 41% opposed to the procedure, and 63%
supported hESC research, with 25% opposed. The numbers in the United Kingdom were
surprisingly similar, with 43% of the British in favor and 38% against therapeutic cloning, with
63% for and 17% against hESC research (Roy Morgan, 2001) (error of +/- 4%). U.S. and U.K.
policies that stem from that time, however, differ tremendously. The U.K. gives national-level
funding to stem cell research and has legislated the allowance of therapeutic cloning. The
difference in policies can be explained by the differences in political institutions.
In the United States, all federal funding for hESC research is allocated as part of the
budget for the National Institutes of Health (NIH), which gave out over $27 billion in 2004 (NIH
Office of Budget, 2005). The NIH is entirely under executive mandate. With the exception of
riders such as the Dickey Amendment, Congress has no ability to direct the use of funding, and
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NIH policy therefore is subject only to the whims of whoever resides in the Oval Office. Under
the Clinton administration, the NIH allowed hESC research with federal funding; under Bush, it
has not. The uncertainty of federal policy distinguishes the United States from other nations.
Yet the powers of the president of the United States are limited by the checks and balance
of the legislature. By contrast, a prime minister cannot stay in office unless he has a majority in
parliament, and therefore any legislation put forth by his government will usually be ratified into
law. Thus in the U.K., where stem cell research has enjoyed strong Labour party support, even
though a significant number of citizens believe that therapeutic cloning should not be allowed,
the government's policy has been one of the most liberal in the world.
In a country with a divided populace, however, it is unlikely that either a complete ban or
complete allowance could become law under a presidential system. And as the ethics of stem
cell research are related to views on abortion, public opinion will likely remain polarized in the
United States; Roe v. Wade, the 1973 decision that guaranteed abortion rights, still generates
controversy. Even a bill to ban reproductive cloning--arguably the least ethically divisive
procedure--did not pass in the Senate in 2002 (Stolberg, 2002). And though moderate
Republicans have been trying to pass a bill to allow the use of federal funds for discarded
embryos, and 58 senators signed a letter to President Bush to modify his policies (Weiss, 2005),
the executive branch, regardless of which party holds the Presidency, may fiercely guard its
power to allocate federal funding. Any attempt by the legislature to change the balance of power
is likely to be vetoed.
The federal-state system of the United States gives states jurisdiction over any area not
specifically covered by federal law. Thus the silence of the national government allows an
extreme variation of policies among state governments (Table 6-2), and this variation may have
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kept U.S. scientists from going abroad. Though most states have not passed any laws and
therefore remain as equally permissive as federal statutes, California and New Jersey explicitly
allow and provide funding for hESC and even SCNT experiments (Murphy, 2005; Kocieniewski,
2005). Massachusetts will shortly pass a bill (overriding Governor Mitt Romney's veto) that
sanctions hESC (Belluck, 2005).
Policy State
Prohibition of research on embryos Arkansas, Iowa, Michigan, North Dakota, South
Dakota,
Prohibition on IVF embryos Louisiana
Allowance of derivation of hESC from somatic California, Massachusetts, New Jersey, Wisconsin
nuclear cell transfer (therapeutic cloning)
Table 6-2. Summary of current hESC policies of selected states (Ackerman, 2004)
State funding is an important development for the continuation of research. As much as
private companies have driven this research forward, basic science is rarely profitable. Geron
Corporation, one of the major private backers of hESC research in the United States, reported
that:
... [a]s of December 31, 2004, our accumulated net loss was approximately $336.1 million.
Losses have resulted principally from costs incurred in connection with our research and
development activities and from general and administrative costs associated with our
operations. We expect to incur additional operating losses and, as our development efforts
and clinical testing activities continue, our operating losses may increase in size.
Substantially all of our revenues to date have been research support payments under
collaboration agreements and revenues from our licensing arrangements. We may be
unsuccessful in entering into any new corporate collaboration that results in revenues. We
do not expect that the revenues generated from these arrangements will be sufficient alone
to continue or expand our research or development activities and otherwise sustain our
operations (Geron Corporation, 2004)
Geron, and WiCell, Inc., another private firm, funded the initial University of Wisconsin cell line
derivation experiments and patented the processes they developed. One would have expected the
company to benefit substantially from the Bush policy as they could have sold their cells and
licensed their technologies at a premium to researchers seeking federal funding. However, the
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NIH negotiated a collaborative agreement where other researchers who use federal money would
be able to purchase the cells at fair use value ($5000) if they forgo commercial rights (United
States Public Health Service, 2001). This was a highly unusual arrangement; private companies,
unlike academics, are not committed to sharing information or technologies. In fact, though
conceding on their rights to the original patents, Geron has since received over 175 patents on
various other stem cell processes, it also is in a patent battle with Advanced Cell Technologies of
Worcester, MA over a SCNT process (Geron Corporation, 2004). Increased private funding may
have the effect of driving research underground and significantly curtailing the publication of
new advances.
On the other hand, private involvement is inevitable. The Bayh-Dole Act of 1980
requires universities and other non-profit institutions to collaborate with commercial institutions
through technology licensing. Specifically, they have the responsibility to disclose, patent and
commercialize any invention developed using federal funding (Bayh-Dole, 1980). Therefore,
universities would be required to license stem cell processes, found start-ups or sell patents to
private firms, and it is likely that federal funding would lead to the same transparency problems
in the future.
State funding, however, has no such regulations, and for this reason may be a funding
source that restricts knowledge transfer the least. In 2004, California voters passed Proposition
71 in 2004 to borrow $3 billion over the next 10 years to support the research (Murphy, 2004).
New Jersey has proposed $380 million and has already begun work on a stem cell research
center (Kocieniewski, 2005). Massachusetts and New York legislatures are currently debating
the level of state funding they are able to provide to researchers (Lewis, 2005; McIntire, 2005).
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The Bush administration's policies, which seemed to have the effect of restricting U.S.
research, may paradoxically have had the opposite effect. The risk of a "brain drain" of U.S.
scientists appears to have been minimized by the increased state and private funding for hESC
research. In the next section we will explore this conclusion using publication data.
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Chapter 7
Analysis of Publication Data
7.1 Methodology
7.1.1 Database
A complete database of every major non-review human embryonic stem cell article
published since 1998 was compiled using PubMed. Pubmed is a widely-used, searchable
database of biomedical literature maintained by the National Library of Medicine. Its primary
component is MedLine, a database of over "4,800 biomedical journals published in the United
States and 70 other countries" (PubMed, 2005). The comprehensive coverage of this database
makes it likely that our compiled database contains a citation of most, if not all, relevant articles.
Our database maps several features:
- Date of Publication
m Authors, including institution and state or country
- Funding sources, where published
- Citation frequency (using ISI Web of Science and scholar.google.com)
It can therefore be used to track researchers who move between institutions, to gauge the
importance of publications by the number of citations, to map collaborations between
researchers, and to identify any potential impact of funding availability and policy on publication
frequency.
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The question of whether there is a "brain drain" may be explored in several ways.
Published researchers who change institutions can easily be tracked; this method is the most
direct but gives little information on previously unpublished scientists who choose institutions
and countries based on the possibility of pursuing hESC research. However, a country's depth of
expertise and attractiveness to new scientists may be broadly measured by comparing the number
of scientists in each state or country, as well as by comparing the rates of change from year to
year. Finally, we can track the international collaborations that have resulted in publication.
The more complex, and perhaps more interesting, question is whether the United States
has fallen behind its international colleagues. There are several metrics that might give insight
into this question: how prolific an author is (the "quantity" of publications) can tell us the pace of
research in his laboratory, while the frequency of citation (the "quality" of publications) can tell
us how noteworthy or relevant his work is to the scientific community.
Finally, we can explore the relevance of federal funding to stem cell publications across
countries to see if federal funding is correlated with higher numbers of publications and higher
citations.
7.1.2 Limitations of the criteria
These criteria have several limitations. A truly objective frequency is impossible to
obtain because an element of subjectivity is always present in the choice of journals or books that
are searched. However, we have used the standard citation index--ISI Web of Science--to search
for the number of citations. Publications also only highlight new research, and scientists who
replicated experiments are unlikely to be published for duplicate work. For example, scientists
in the Czech Republic were able to derive stem cells in 2003 using the procedures developed
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American and Israeli scientists five years ago. These results were not published in any journal
covered by PubMed. However, such omissions are not relevant to the issue we are studying,
which is whether the U.S. is falling behind in conducting noteworthy and novel research.
Publication data may not include everybody who is working on hESC research, but it will
include all those at the forefront.
Another issue is that because of much of the research is privately funded, not all advances
may be published. For private companies who have invested their capital in the expectation that
basic science advances will eventually lead to profitable therapies, sharing knowledge in the
academic network may not be as attractive as keeping a potential trade secret. When President
Bush made his announcement in 2001, his claim that over 60 stem cell lines might already exist
was met with incredulity from some scientists. Health and Human Services Secretary Tommy
Thompson explained, "Research with ES cells is such a new endeavor that laboratories,
companies and researchers are keeping their work guarded, as you can understand... A lot of the
research was going on behind closed doors" (qtd. in Cimon, 2001). The secrecy about research
may still exist.
More problematically, the peer review process that accepts articles for publication may
be biased, thus frequent publication may not be commensurate to true progress in research. In
one famous study, Peters and Ceci (1981) changed the names and institutional affiliations of
authors on twelve papers and resubmitted the slightly altered manuscripts to peer-reviewed
journals that had originally published the same papers 18 to 32 months before. While three of
the papers were caught as duplications, nine made it through the screen, and of these eight were
rejected. While this result was interpreted as demonstrating the bias of reviewers towards
authors from prestigious institutions, it is not inconceivable that the name of an established
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researcher also might influence frequency of publication as well as the visibility of a journal in
which an article might eventually be accepted.
Citation frequency is also an imperfect measure of quality. Journals are stratified in
importance and an article published in a prestigious journal such as Nature will be read widely,
and therefore is likely to be cited more often. This metric may also give less weight to the new
and novel: groups that perform similar research will cite each other, but a maverick group that
performs interesting but unique research could be missed entirely. In addition, the number of
citations is a cumulative figure, which can skew the measure of notability towards older papers
or papers that describe the methodology of new procedures as pioneering work is transferred to
other groups. As time passes and new methods are developed, the importance of old methods
paper to current researchers may become less clear.
Despite these misgivings, publication and citation frequency are commonly used metrics
in academic circles. Both may influence tenure and promotion cases as a demonstration of
international recognition for excellence in research. Citations in particular, according to the ISI
Web of Knowledge, a database of frequency,
... [are] a direct measure of influence on the literature of a subject, and it is also a strong
indicator of scientific contribution, since it is derived from pattern of interaction among
millions of published articles. When one researcher cites another's work, he/she is
acknowledging the relevance of that work to the current study. The interaction is both
highly specific, and highly informed; it is a statement by an author of the scholarly
relatedness of two works (McVeigh, 2001).
Also, because hESC research is high profile and still very much in its infancy, publication
data may in fact be more even suited to measuring the influence of researchers than in other
fields. At this stage, most new research is noteworthy and may be considered for publication
regardless of the prestige of the author, provided the science is sound. And as the field is no
more than seven years old at the date of this writing, even "older" papers are likely relevant to
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current practice, and it is possible to control for the year (or month) of publication to avoid
comparing the citation frequency of newer to older papers.
Citation frequency will obviously be less practical for newer papers, as there are simply
fewer citations because of the lag between publication and knowledge transfer through the
scientific press. Yet while the impact of new research cannot be ascertained immediately,
exceptional or controversial papers may nevertheless stand out. Citation frequency should also
give a more objective view of the importance of a paper than assigning subjective ranks to a
certain journal's importance because the importance of a journal and its wider readership is
implicit in the metric.
Finally, we have chosen not to use regression analysis to correlate U.S. federal funding
with publication rate or citation frequency for this analysis because of the problem of omitted
variables and because the NIH does not publish the amounts of the grants. However, we have
compared the means of federally funded vs. non-federally funded populations and have
attempted to ascertain if there is a significant difference between the mean number of
publications, as well as the mean number of citations for each paper.
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7.2 Results and discussion
7.2.1 Is there a brain drain?
Only three published hESC scientists have changed institutions in the past seven
years:
- Dr. Shulamit Levenberg left a post-doctoral position at MIT to become an assistant
professor at the Technion in Israel in 2002.
" Dr. Benjamin Reubinoff finished his Ph.D. in Australia at Monash University in 1999
and became director of the Hadassah Human Embryonic Stem Cell Research Program
at the Hadassah University Medical Center in Israel.
- Dr. Mahendra Rao left an associate professorship at University of Utah in 2001 to
become director of the Stem Cell Group of at the National Institute on Aging's
Laboratory of Neuroscience in Bethesda, Maryland.
These moves all appear to be for professional or personal reasons. All received
promotions, and in the first two cases, returned to their country of origin.
Figure 7-1. Human embryonic stem cell researchers by country (1998-2005)
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We can also analyze the relative attractiveness of the United States to other nations by
comparing the locations of published researchers. Over the past seven years, 783 scientists have
worked with human embryonic stem cells; of these, 287 were at U.S. institutions (Figure 7-1),
almost double the number of scientists in South Korea and triple the number in the UK. The
United States has also had the highest number of published researchers in five of the past seven
years, as can be seen in Table 7-1.
Rank 2005* 2004 2003 2002 2001 2000 1998
1 USA 89 USA 169 USA 64 USA 15 Israel 25 Israel 15 Wisconsin 6
2 S KoreaA 61 S. KoreaA 60 Israel 31 Israel 11 USA 20 USA 7 Israel 1
3 China 28 UK 49 UK 20 Netherlands 9 Australia 4 Australia 2
4 UK 21 Israel 46 S. Korea 16 UK 7 Germany 5 Singapore 2
5 Singapore 19 Sweden 33 Netherlands 9 Singapore 5 - -
*up to May 1, 2005
Asome South Korean papers list 15 researchers; they may have a different standard for authorship
Table 7-1: Top five countries by number of researchers per year
By these two measures it appears the United States has not lagged behind other countries
in attracting researchers. Of course we do not know how many researchers may have come to
the United States if more funding were available, but by this comparative result we are optimistic
about the future of U.S. stem cell research provided that no federal ban is enacted.
The limiting of federal funding and the uncertainty of federal policy has also has not
prevented research groups in the United States from striking up collaborations with foreign
scientists. According to the database, of the 198 hESC papers that have been published since
1998, 27 have been international collaborations, and of those, U.S. scientists collaborated with
scientists from eight other countries on 18 different papers. A network map of all collaborations
may be seen in Figure 7-2. More specifically, since 2002 after the policy was enacted,
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international collaborating groups have published 20 papers, and U.S. scientists have been
involved in 14 papers with scientists from seven countries.
japan
Netherlands
canada
Franoe /
Gerany
ciece
* France and Greece were the nations of two visiting scientists in U.S. labs
Figure 7-2: Network map of all international collaborations (1998-2005)
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7.2.2 Is the U.S. falling behind?
200 papers on human embryonic stem cell research have been written in the past seven
years by 793 authors (Figure 7-3). Researchers in the United States were the first authors on 74
of them, and co-authors on seven more. This distribution is broken into years in Table 7-2. By
this measure, since 2002, the United States has published more papers in a given year than any
other country. Despite the restrictions on federal funding, the United States is still the most
prolific nation in human embryonic stem cell research.
USA
36%
Other Canada
6% 4%
Sweden
4%
Australia
4%
China
5%
Singapore
5%
UK
9%
Israel
16%
Figure 7-3. Total number of publications by country of first author (1998-2005)
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Country Total 2005* 2004 2003 2002 2001 2000 1998
USA 71 16 35 11 3 5 0 1
Israel 34 2 12 8 2 6 4
Australia 8 2 2 2 1 0 1
Netherlands 2 0 0 1 1
ingapore 9 3 4 1 1
China 9 4 4 0 1
UK 18 3 8 5 2
weden 7 2 4 1
Canada 7 1 5 1
South Korea 23 9 11 3
Russia 1 0 0 1
ermany 2 0 2
Iran 1 0 1
Japan 4 2 2
Belgium 1 0 1
Spain 1 1
* Until May 1, 2005. Countries in order of first publication
Table 7-2. Number of publications by year by country of first author (1998-2005)
We might also be curious about the rate of change in publication frequency for a given
country. However, this metric is easily manipulated because the rates may vary depending the
choice of month, quarter or year. And while the metric would most likely be used to compare
the technical progress in two countries, the rate of publication depends on many other factors.
Frequent prior publication in one year may demonstrate that a country has technical expertise,
good teams and sufficient funding, but it is no guarantee that it will succeed at ever-higher rates
in the future.
Citation data is a better metric of technical progress. Highly cited papers show novelty
and relevance of research to the scientific community. According to Table 7-3, the U.S. has the
highest aggregate number of citations, and since 2002, when federal funding became available
for selected stem cell lines, U.S. researchers have consistently had the most citations per year. In
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addition, U.S. scientists have been the first authors for the most-cited papers in the past five
years (Table 7-4).
Country Total 2005* 2004 2003 2002 2001 2000 1998
USA 2587 11 280 352 248 632 0 1064
Israel 1411 0 51 92 76 715 477
ustralia 353 0 12 3 0 0 338
UK 171 0 34 56 81
Singapore 107 1 1 22 83
South Korea 134 1 112 21
Netherlands 81 0 0 48 33
Sweden 4 0 16 28
anada 43 0 13 30
China 2 0 2 0 0
Iran 1 0 1
Belgium 1 0 1
apan 1 1 0
Russia 0 0 0
Germany 0 0
Spain _ _0
*up to May 1, 2005
Table 7-3. Total Web of Science citations by year by country of first author (1998-2005)
Rank 2005* 2004 2003 2002 2001 2000 1998
1 MJ Martin WS Hwang TP Zwacka S Levenberg SC Zhang BE Reubinoff JA Thomson
UCSD SNU U Wisc MIT U of Wisc Monash U. U of Wisc
USA South Korea USA USA USA Australia USA
(6) (89) (52) (110) (209) (338) (1064)
2 Y Verlinsky N Sato C Mummery M Richards I Kehat M Amit
Reprod Gen Rockefeller U Hubrecht NUS Technion Technion
USA USA Netherlands Singapore Israel Israel
(2) (59) (48) (83) (204) (179)
3 RH Xu CA Cowan M Amit C Xu C Xu J Itskovitz-Eldor
U of Wisc Howard Hughes Technion Geron Corp Geron Corp. Technion
USA USA Israel USA USA Israel
(2) (46) (44) (78) (180) (143)
4 L Daheron N Sato RH Xu S Assady M Schuldiner
--four papers Whitehead Inst. Rockfeller U U of Wisc Technion Technion
have one USA USA USA Israel Israel
citation (31) (40) (60) (179) (131)
5 MK Carpenter Y Ma M Drukker BE Rubinoff M Tzukerman
--49 papers Geron Corp. U of Wisc Hebrew U Hebrew U Technion
have no USA USA Israel Israel Israel
citations (26) (39) (58) (125) (24)
*Up to May 1, 2005; citation frequency is low and the ranking will likely vary over the next year
Table 7-4: Authors, groups, countries and citation numbers of the top five most cited papers
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7.2.3 What is the relationship between federal funding and publication?
It seems that the United States, far from falling behind, is still leading the way in human
embryonic stem cell research. But we may also ask if federal funding is correlated with the
quantity and quality of publications.
One way to look at this question is to look at the relative proportion of papers that have
been funded through national-level funding. Of the 198 papers, 90 (45%) were published by 35
groups funded wholly or in part by federal funding (Table 7-5). These groups went on to publish
73 papers with private funding alone. The remaining 21 groups published 35 papers. Thus
62.5% of the groups published 82.3% of the papers. It is even more striking that the 22 groups
who have received NIH or other U.S. federal funding have published 101 papers, or a little over
half of the research.
Funding Type Publications
All Federal 36
Some Federal 56
Other (private, state*, etc.) 106
*regional funding in other countries considered to be state funding
Table 7-5: Funding sources for published papers (1998-2005)
Groups with federal funding published an average of 5.11 papers, while groups without
federal funding published an average of 1.65 papers. On first glance, this would suggest that
U.S. federal funding is correlated with higher publication rates. But the frequency distributions
of both groups are not normal, as can be seen by the long positive tails in the histograms in
Figures 7-4 and 7-5. In both cases, outlier groups publish far more than the average.
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Figure 7-4: Number of papers published by U.S. federally funded researchers (1998-2005)
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Figure 7-5: Number of papers published by non-US federally funded researchers (1998-2005)
The one-sided t-test is a standard way to test a hypothesis that a mean is greater or less
than a certain value. But because our distribution of papers is skewed, we cannot use the normal
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one-sided test. However, we can adjust for the skew by using Johnson's modified t-test (1978).
In this test, the modified t-statistic is
ti= [(3 -p)+(p, /6.2N]s2 /N (1)
and the confidence interval is
k + (u /60.2N)± ta12 vSI4K (2)
where i is the sample mean, p is the population mean, .2 ,4 3 are the second and third central
moments of the sample, s is the standard deviation, N is the sample size, v = N -1 are the
degrees of freedom, and a is the level of significance. The confidence intervals for the means of
the federal and non-federal distributions may be seen in Table 7-6.
Federally funded researchers Non-federally funded researchers
Mean - 5.11 Mean x 1.65
St. Dev. S 5.49 St. Dev. s 1.81
Sample Size N 19 Sample Size N 20
D. of Freedom 18 D. of Freedom 19
to.025,18 (95% sig.) 2.101 t 0.025,19 (95 % sig.) 2.093
Adjusted Mean 5.19 Adjusted Mean 1.52
95% Confidence Interval 2.55-7.80 95% Confidence Interval 0.67-2.37
Table 7-6: Average number of publications of federal and non-federal researchers (1998-2005)
We are therefore 95% confident that the average number of publications for the federally
funded researchers is between 2.55 and 7.80, and similarly, we are 95% confident that the
average number of publications for the non-federally funded researchers is between 0.67 and
2.37. Thus this difference is statistically significant, and it appears that researchers who have
received federal funding publish more than researchers who do not. However, we do not know if
this effect is causal. Federal funding may increase the rate of publication. The funding level is
not trivial: from 2001 to 2005, the NIH set aside approximately $30 million specifically for
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hESC research. And while funding is not a guarantee of success, it can help a lab to buy better
equipment and hire more people. In addition, winning a federal grant may also help groups
attract private funding.
However, it could also be that the NIH and other U.S. funding bodies may choose groups
with proven track records and technical expertise. We can look directly at the NIH database of
biomedical grants, the Computer Retrieval of Information on Scientific Projects (CRISP), for
some evidence to support the latter hypothesis. According to CRISP, 89 grants have been
awarded so far for hESC research. We cannot find out which institutions applied for but did not
receive grants, so we cannot conclude that early movers were favored. However, we can note
that 27 grants, or nearly one-third, were given to 16 groups who had already published papers
about stem cell research before August 9, 2001. Several of these grants were infrastructure
grants to guarantee the robustness of the stem cell lines available to federal researchers including
grants made to four foreign groups that had derived lines before August 9, 2001. This would
suggest that the NIH did favor early entrants.
There also appears to be a relationship between federal funding and number of citations
in a given year. Again, the vast majority of the most highly cited papers were by federally
funded groups (Table 7-7), which is consistent with either an advantage conferred to grant
recipients or a process that favors early movers. However, the modified one-sided t-test is
inconclusive; Table 7-8 is given as an example for the statistics for 2003. The values for the
means lie within the confidence intervals and we cannot draw any conclusions for whether
federally funded researchers on average have a higher number of citations.
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Rank 2005* 2004 2003 2002 2001 2000 1998
1 UCSD SNU U of Wisc MIT U of Wisc Monash U. U of Wisc
USA South Korea USA USA USA Australia USA
(6) (89) (52) (110) (209) (338) (1064)
2 Repro Gen Rockefeller U Hubrecht Lab NUS Technion Technion
USA USA Netherlands Singapore Israel Israel
(2) (59) (48) (83) (204) (179)
3 U of Wise Howard Hughes Technion Geron Corp Geron Corp. Technion
USA USA Israel USA USA Israel
(2) (46) (44) (78) (180) (143)
4 --four Whitehead Inst Rockefeller U U of Wisc Technion Technion
papers USA USA USA Israel Israel
have one (31) (40) (60) (179) (131)
citation
5 --49 Geron Corp. U of Wisc Hebrew U Hebrew U Technion
papers USA USA Israel Israel Israel
have no (26) (39) (58) (125) (24)
citations
Table 7-7: Groups, funding source, countries and citations for the top five most cited papers
*Up to May 1, 2005; Bold indicates recipients of U.S. or foreign federal funding
Citations data for federally funded papers Citation data for non-federally funded papers
Mean 3 16.36 Mean T 24.33
St. Dev. s 16.09 St. Dev. s 14.81
Sample Size N 22 ample Size N 20
D. of Freedom 21 D. of Freedom 19
0.010, 22 (90% sig.) 1.721 t0 0 10 , 1 1 (9 0 % sig.) 1.796
Adjusted Mean 16.44 Adjusted Mean 24.29
90% Confidence Interval 10.54-22.35 90% Confidence Interval 16.62-31.97
Table 7-8: Average number of citations, federal and non-federal funding in 2003
Finally, many of the most cited papers, even from foreign groups, was carried out on cell
lines that had NIH approval (Table 7-9). This is a surprising result; as of May 23, 2004, 128
stem cell lines had been created since the enactment of President Bush's stem cell policy (Cook,
2004) and as we have seen, many critics of the policy suggested that the most interesting
research would be performed abroad. But perhaps again due to a strong early-mover advantage,
up until quite recently, most of the noteworthy research has been performed by groups that had
already derived stem cells before August 9, 2001 that benefited by abiding by federal funding
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restrictions. In fact, of the total 198 papers, 139 were performed on approved stem cell lines and
could have been federally funded, even though in actuality the funding sources were a mix of
private and public money.
Rank 2005* 2004 2003 2002 2001 2000 1998
1 UCSD SNU U of Wisc MIT U of Wisc Monash U. U of Wisc
H1 SCNT-hES-1 H1.1 H9 clone Hi, H9, HES-1, HES-2 H1, H7, H9,
USA South Korea USA USA H9.2, H14 Australia H13, H14
(6) (89) (52) (110) USA (338) USA(209) (1064)
2 Repro Gen Rockefeller U Hubrecht Lab NUS Technion Technion
18 new lines H1, BGN1, HES-2 HES-3, Hi, H7, H9, H9.1, H9.2
USA BGN2 Netherlands HES-4 H14 Israel
(2) USA (48) Singapore Israel (179)
(59) (83) (204)
3 U of Wisc Howard Hughes Technion Geron Corp Geron Corp. Technion
H1, H9, HUES1- 13, 16, H9 H1, H7, H9, H9 H9 clone
H14 HUES17 Israel H9.1, H9.2 USA Israel
USA USA (44) USA (180) (143)
(2) (46) (78)
4 --four papers Whitehead Inst Rockefeller U U of Wisc Technion Technion
have one H1, H7, H9 H1, HES-3 H1, H7, H9, H1, H1.1, H9 clone
citation USA USA H14 H9.2 Israel
(31) (40) USA Israel (131)
(60) (179)
5 --49 papers Geron Corp. U of Wisc Hebrew U Hebrew U Technion
have no H1, H7, H9, H9 HES-1 H9 H9
citations H14 USA Israel Israel Israel
USA (39) (58) (125) (24)
(26)
*Up to May 1, 2005
Table 7-9: Stem cell lines used in most-cited papers, 1998-2005
Bold indicates eligibility for U.S. federal funding
As startling as this result is, it appears that times are changing. The most cited paper of
2004 was the derivation of stem cells from a cloned blastocyte, which is illegal in many
countries and ineligible for federal funding in the United States. Also, the third most cited paper
that year was the derivation of 17 stem cell lines by Harvard researchers using private funds,
intended for use by non-federally funded researchers. Finally, the most cited paper of 2005 so
far has been a paper that discusses that stem cell lines cultured on murine feeder cells may be
contaminated and useless for therapeutic treatments. Both of these groups had not published a
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paper before 2003. It appears, therefore, that the early mover advantage is becoming
increasingly less important.
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Chapter 8
Summary and Future Directions
Our analysis of the current state of hESC research has shown that the quantity and quality
of U.S. research does not seem to have declined relative to research performed in other countries.
Early groups with a strong technical advantage, even in other countries, had a strong incentive to
abide by U.S. federal funding guidelines. There was a definite correlation between the quantity
of papers published and federal funding because these early groups made many advances.
However, we also appear to be on the cusp of great change because the research is becoming
more widespread, more groups are gaining expertise and new state funding sources are becoming
available.
The analysis of the publication data was intended to be a quantitative look at the status of
research in the United States and other nations, and the methodology should remain equally
relevant in future years. However, as described, this indirect methodology does have limitations.
The only way to accurately assess the opinions of stem cell scientists is a direct survey. It would
be interesting to see if graduate students and post-doctoral fellows interested in stem cell
research consider the uncertainty of federal policy when deciding which positions to accept. A
survey could also ascertain the opinions of private groups that choose not to publish in the public
domain.
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We also have not considered the wealth of promising research taking place with other
types of cells, animal embryonic stem cells and human adult and umbilical cord stem cells
among them. Those with expertise with other types of stem cells may be able to make a switch
to working with human embryonic stem cells. Understanding the issues that affect the decisions
of these scientists would allow a better analysis of the future directions of hESC research.
In recent months, Congress has asked President Bush to reconsider his stem cell policy
and open up federal funding for cryopreserved embryos. This policy has much support from the
legislature, including moderate Republicans, but it is unlikely that any change will occur because
the executive will likely not want to concede his power to set research policy unless public
opinion becomes overwhelming. But it is highly improbably that the public will coalesce on this
issue because of the great divide in opinion on the status of the embryo and other ethical
considerations.
But the impasse on a federal level has left research open for U.S. scientists, and the influx
of state funding will likely stave off any future "brain drain" to other countries. It will also allow
new research groups in the U.S. to innovate, as, unlike existing groups, they will not have an
incentive to abide by federal guidelines. President Bush's policy, far from restricting hESC
research, has nearly guaranteed that researchers in the United States will continue to lead the way
in this controversial area for the foreseeable future.
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Appendix A
Matlab Code
1. Analysis.m
% 1 micron=20 pixels
import picture
[X]=imread('actin4.jpg');
%show image in image viewer
figure(1);
imshow(X);
zoom on;
pause;
hold on;
%choose points on image. initially, the list of points is empty.
xy = [];
n = 0;
% Loop, picking up the points.
disp('mouse button picks points.')
disp('option+button picks last point.')
but = 1;
while but == 1
[xi,yi,but] = ginput(1);
plot(xi,yi,'ro')
n = n+1;
xy(:,n) = [xi;yi];
end
% Interpolate with a spline curve and finer spacing.
t = 1:size(xy,2);
ts = 1: 0.001: size(xy,2);
xys = spline(t,xy,ts);
%Plot the interpolated curve.
plot(xys(1,:),xys(2,:),'b-');
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%translate interpolated points into pixels
B=round(xys);
%get rid of non-essential points
x=B(1,:);
y=B(2,:);
z=ones(size(B,2), 1);
S=sparse(x,y,z);
F=full(S);
K=bwmorph(F,'skel');
%get coordinate values of points
[x,y,v]=find(K);
K2=[x,y];
%Highlight selected pixels K
y=K2(:,1);
x=K2(:,2);
z=ones(size(K2, 1),1);
S=sparse(x,y,z);
F=full(S);
%reorder vector
A1=reorder(K2);
%find angles of tangent vectors
A2=angle(A1 ,4);
%writes vector to new vector cell V
V=new({A1 },V);
%writes angle to new angle cell A
A=new(A2,A);
1.1 Reorder.m
function[AI=reorder(B);
%takes column vector and reorders it into consecutive points
%assumes that B is a single skeletonized line
E=[0,0];
for k=1:size(B);
[T,M]=neighbor(B,B(k,:));
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if size(M,1)==1;
e=size(E);
E(e(1)+1,:)=B(k,:);
end
end
E=E(2:size(E, 1),:);
A=E(1,:);
%check neighbor points
while size(A, 1)<size(B, 1);
i=size(A, 1);
[T,M]=neighbor(B,A(i,:));
R=zeros(size(M,1),1); %dummy
%check if point has already appeared in A. if a neighboring point is
%in A already, a vector with all the non-zero entries of R is created.
for j=1:size(M,1);
for k=1:size(A,1);
if M(j,:)==A(k,:);
R(j)=j;
break
end
end
end
R=find(R);
%if R is empty (i.e. the point is not in A, the point is written into
%A. if R is not empty, M is rewritten without it and the remaining
%points written into A)
if isempty(R)==1
A(i+1,:)=M(1,:);
i=i+1;
else
for k=1:size(R,1);
M(R(k),:)=[0,0];
end
for k=1:size(M,1);
if M(k, 1)-=O,
A(i+l,:)=M(k,:);
i=i+1;
end
end
end
end
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1.1.1 Neighbor.m
function [T,M]=neighbor(B,i)
%checks if point i (x,y) has any neighbors in vector B
b=size(B);
x=i(1);
y=i(2);
t=[x,y];
%create vector T of neighboring pixels
T(2,:)=[x-1,y+1];
T(2,:)=[x,y+];
T(3,:)=[x+,y+1];
T(4,:)=[x-1,y];
T(5,:)=[x+ l,y];
T(6,:)=[x-1.,y-1];
T(7,:)=[x,y-I];
T(8,:)=[x+1,y-1];
M=[0,0];
%check if neighboring pixels are in vector B; if they are, writes %pixels to vector m
for j=1:8;
for k=1:b(1);
if T(j,:)==B(k,:);
m=size(M);
M(m(1)+1,:)=T(j,:);
break
end
end
end
M=M(2:size(M,1),:);
1.2 Angle.m
function[X]=angle(B,n);
%find angles along reordered filament B between vectors of length n %pixels
for j=1:size(B,1)-n;
%define initial vector vO for all j along the filament
vO=B(n+j-i,:)-B(j,:);
%find angles along filament and record to vector 0
for i=j:size(B,1)-n;
C=(B(n-l+i,:)-B(i,:));
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O(i-j+ 1, 1)=(dot(c,vO)/sqrt(dot(c,c)*(dot(vO,vO))));
end
%record angle vector 0 to cell X
X(j)=[{o}];
clear 0;
end
1.3 New.m
function[C]=new(X,C);
%writes vector X or cell {X} to a new cell
C=[C X];
2 Average.m
function[Ma,Mf,M]=average(C,p);
%takes vectors greater than length p in cell C and averages values, %then plots averages
%find maximum length of vector in C
clear S;
for i=1:size(C,2);
if size(C{i},1)>=p,
S(i,:)=[size(C{ i}, 1),i];
else S(i,:)=[0,0];
end
end
a=find(S(:,2));
smax=max(S(:, 1));
%create matrix M with all vectors with appropriate number of zeros added %to shorter vectors
M=zeros(smax,length(a));
for i=1:length(a);
M(1: size(C{ a(i) }, 1),i)=C{ a(i) };
end
%Mfinal (cut to size of input p)
Mf=M(1:p,:);
%Maverage (averages along the pixel length)
Ma=sum(Mf,2)/length(a);
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3 Expfit.m
function [estimates, model] = expfit(xdata, ydata)
% Call fminsearch with a random starting point.
start-point = rand(1, 2);
model = @expfun;
estimates = fminsearch(model, start_point);
% expfun accepts curve parameters as inputs, and outputs sse,
% the sum of squares error for A * exp(-lambda * xdata) - ydata,
% and the FittedCurve. FMINSEARCH only needs sse, but we want to
% plot the FittedCurve at the end.
function [sse, FittedCurve] = expfun(params)
A= 1;
lambda = params(2);
FittedCurve = A .* exp(-lambda * xdata);
ErrorVector = FittedCurve - ydata;
sse = sum(ErrorVector .^ 2);
end
end
4 Plotexp.m
function[xdata]=plotexp(Ma,estimates);
xdata=[1:size(Ma)]';
ydata=Ma;
figure(3)
plot(xdata, ydata, '*')
hold on
FC=exp(-1*estimates(2) * [1:size(Ma)]');
plot([ 1:size(Ma)]', FC, 'r');
FC2=exp(-1*0.0016 * [1:size(Ma)]');
plot([1:size(Ma)]', FC2, 'g');
xlabel('Pixels')
ylabel('Average of Angles')
title(['Persistence Length Exponential Function']);
legend('data', 'calculated fit lp=3.85 um','Gittes Value lp=17.7 um')
hold off
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Appendix B
President Bush's Remarks on Stem Cells, August 9. 2001
Good evening. I appreciate you giving me a few minutes of your time tonight so I can discuss
with you a complex and difficult issue, an issue that is one of the most profound of our time.
The issue of research involving stem cells derived from human embryos is increasingly the
subject of a national debate and dinner table discussions. The issue is confronted every day in
laboratories as scientists ponder the ethical ramifications of their work. It is agonized over by
parents and many couples as they try to have children, or to save children already born.
The issue is debated within the church, with people of different faiths, even many of the same
faith coming to different conclusions. Many people are finding that the more they know about
stem cell research, the less certain they are about the right ethical and moral conclusions.
My administration must decide whether to allow federal funds, your tax dollars, to be used for
scientific research on stem cells derived from human embryos. A large number of these embryos
already exist. They are the product of a process called in vitro fertilization, which helps so many
couples conceive children. When doctors match sperm and egg to create life outside the womb,
they usually produce more embryos than are planted in the mother. Once a couple successfully
has children, or if they are unsuccessful, the additional embryos remain frozen in laboratories.
Some will not survive during long storage; others are destroyed. A number have been donated to
science and used to create privately funded stem cell lines. And a few have been implanted in an
adoptive mother and born, and are today healthy children.
Based on preliminary work that has been privately funded, scientists believe further research
using stem cells offers great promise that could help improve the lives of those who suffer from
many terrible diseases--from juvenile diabetes to Alzheimer's, from Parkinson's to spinal cord
injuries. And while scientists admit they are not yet certain, they believe stem cells derived from
embryos have unique potential.
You should also know that stem cells can be derived from sources other than embryos--from
adult cells, from umbilical cords that are discarded after babies are born, from human placenta.
And many scientists feel research on these type of stem cells is also promising. Many patients
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suffering from a range of diseases are already being helped with treatments developed from adult
stem cells.
However, most scientists, at least today, believe that research on embryonic stem cells offer the
most promise because these cells have the potential to develop in all of the tissues in the body.
Scientists further believe that rapid progress in this research will come only with federal funds.
Federal dollars help attract the best and brightest scientists. They ensure new discoveries are
widely shared at the largest number of research facilities and that the research is directed toward
the greatest public good.
The United States has a long and proud record of leading the world toward advances in science
and medicine that improve human life. And the United States has a long and proud record of
upholding the highest standards of ethics as we expand the limits of science and knowledge.
Research on embryonic stem cells raises profound ethical questions, because extracting the stem
cell destroys the embryo, and thus destroys its potential for life. Like a snowflake, each of these
embryos is unique, with the unique genetic potential of an individual human being.
As I thought through this issue, I kept returning to two fundamental questions: First, are these
frozen embryos human life, and therefore, something precious to be protected? And second, if
they're going to be destroyed anyway, shouldn't they be used for a greater good, for research that
has the potential to save and improve other lives?
I've asked those questions and others of scientists, scholars, bioethicists, religious leaders,
doctors, researchers, members of Congress, my Cabinet, and my friends. I have read heartfelt
letters from many Americans. I have given this issue a great deal of thought, prayer and
considerable reflection. And I have found widespread disagreement.
On the first issue, are these embryos human life--well, one researcher told me he believes this
five-day-old cluster of cells is not an embryo, not yet an individual, but a pre-embryo. He argued
that it has the potential for life, but it is not a life because it cannot develop on its own.
An ethicist dismissed that as a callous attempt at rationalization. Make no mistake, he told me,
that cluster of cells is the same way you and I, and all the rest of us, started our lives. One goes
with a heavy heart if we use these, he said, because we are dealing with the seeds of the next
generation.
And to the other crucial question, if these are going to be destroyed anyway, why not use them
for good purpose--I also found different answers. Many argue these embryos are byproducts of a
process that helps create life, and we should allow couples to donate them to science so they can
be used for good purpose instead of wasting their potential. Others will argue there's no such
thing as excess life, and the fact that a living being is going to die does not justify experimenting
on it or exploiting it as a natural resource.
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At its core, this issue forces us to confront fundamental questions about the beginnings of life
and the ends of science. It lies at a difficult moral intersection, juxtaposing the need to protect
life in all its phases with the prospect of saving and improving life in all its stages.
As the discoveries of modem science create tremendous hope, they also lay vast ethical mine
fields. As the genius of science extends the horizons of what we can do, we increasingly confront
complex questions about what we should do. We have arrived at that brave new world that
seemed so distant in 1932, when Aldous Huxley wrote about human beings created in test tubes
in what he called a "hatchery."
In recent weeks, we learned that scientists have created human embryos in test tubes solely to
experiment on them. This is deeply troubling, and a warning sign that should prompt all of us to
think through these issues very carefully.
Embryonic stem cell research is at the leading edge of a series of moral hazards. The initial stem
cell researcher was at first reluctant to begin his research, fearing it might be used for human
cloning. Scientists have already cloned a sheep. Researchers are telling us the next step could be
to clone human beings to create individual designer stem cells, essentially to grow another you,
to be available in case you need another heart or lung or liver.
I strongly oppose human cloning, as do most Americans. We recoil at the idea of growing human
beings for spare body parts, or creating life for our convenience. And while we must devote
enormous energy to conquering disease, it is equally important that we pay attention to the moral
concerns raised by the new frontier of human embryo stem cell research. Even the most noble
ends do not justify any means.
My position on these issues is shaped by deeply held beliefs. I'm a strong supporter of science
and technology, and believe they have the potential for incredible good--to improve lives, to save
life, to conquer disease. Research offers hope that millions of our loved ones may be cured of a
disease and rid of their suffering. I have friends whose children suffer from juvenile diabetes.
Nancy Reagan has written me about President Reagan's struggle with Alzheimer's. My own
family has confronted the tragedy of childhood leukemia. And, like all Americans, I have great
hope for cures.
I also believe human life is a sacred gift from our Creator. I worry about a culture that devalues
life, and believe as your President I have an important obligation to foster and encourage respect
for life in America and throughout the world. And while we're all hopeful about the potential of
this research, no one can be certain that the science will live up to the hope it has generated.
Eight years ago, scientists believed fetal tissue research offered great hope for cures and
treatments--yet, the progress to date has not lived up to its initial expectations. Embryonic stem
cell research offers both great promise and great peril. So I have decided we must proceed with
great care.
As a result of private research, more than 60 genetically diverse stem cell lines already exist.
They were created from embryos that have already been destroyed, and they have the ability to
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regenerate themselves indefinitely, creating ongoing opportunities for research. I have concluded
that we should allow federal funds to be used for research on these existing stem cell lines, where
the life and death decision has already been made.
Leading scientists tell me research on these 60 lines has great promise that could lead to
breakthrough therapies and cures. This allows us to explore the promise and potential of stem
cell research without crossing a fundamental moral line, by providing taxpayer funding that
would sanction or encourage further destruction of human embryos that have at least the
potential for life.
I also believe that great scientific progress can be made through aggressive federal funding of
research on umbilical cord, placenta, adult and animal stem cells which do not involve the same
moral dilemma. This year, your government will spend $250 million on this important research.
I will also name a President's council to monitor stem cell research, to recommend appropriate
guidelines and regulations, and to consider all of the medical and ethical ramifications of
biomedical innovation. This council will consist of leading scientists, doctors, ethicists, lawyers,
theologians and others, and will be chaired by Dr. Leon Kass, a leading biomedical ethicist from
the University of Chicago.
This council will keep us apprised of new developments and give our nation a forum to continue
to discuss and evaluate these important issues. As we go forward, I hope we will always be
guided by both intellect and heart, by both our capabilities and our conscience.
I have made this decision with great care, and I pray it is the right one.
Thank you for listening. Good night, and God bless America.
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Appendix C
Stem Cell Database
The following pages list the 198 hESC papers by year and month of publication, first author
country, journal, title, funding type and cell line. The complete database is included in the
electronic version of this thesis.
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Y1ear IMtonfl CUUNIKY CELLS TYPE ISI Web JOURNAL TITLE
1998 11 WI Derived: Hi, Private/ 1064 Science, Vol 282, Issue 5391, Embryonic Stem Cell Lines Derived from Human
H13, H14, H7, State 1145-1147, 6 November 1998 Blastocysts
H9
2000 2 Israel H9 clone Private 143 Mol Med. 2000 Feb;6(2):88- Differentiation of human embryonic stem cells into
95. embryoid bodies compromising the three embryonic
germ layers.
2000 4 Australia Derived: HES- Private 338 Nat Biotechnol. 2000 Embryonic stem cell lines from human blastocysts:
1, HES-2 Apr;18(4):399-404. somatic differentiation in vitro.
2000 10 Israel H9 clone Private 131 Proc Natl Acad Sci U S A. Effects of eight growth factors on the differentiation of
2000 Oct 10;97(21):11307-12. cells derived from human embryonic stem cells.
2000 11 Israel H9. 1, H9.2 Private 179 Dev Biol. 2000 Nov Clonally derived human embryonic stem cell lines
15;227(2):271-8. maintain pluripotency and proliferative potential for
prolonged periods of culture.
2000 12 Israel H9 Private 24 Mol Biol Cell. 2000 Identification of a novel transcription factor binding
Dec;11(12):4381-91 element involved in the regulation by differentiation of
the human telomerase (hTERT) promoter.
2001 4 Israel H9 Private 63 Cuff Biol. 2001 Apr Establishment of human embryonic stem cell-
3; 11(7):514-8. transfected clones carrying a marker for undifferentiated
cells.
2001 8 Israel H9.2 Federal/ 204 J Clin Invest. 2001 Human embryonic stem cells can differentiate into
Private Aug;108(3):407-14. myocytes with structural and functional properties of
cardiomyocytes.
2001 8 Israel H9 Private 179 Diabetes. 2001 Insulin production by human embryonic stem cells.
Aug;50(8):1691-7.
2001 9 Israel H9 Private 87 Brain Res. 2001 Sep Induced neuronal differentiation of human embryonic
21;913(2):201-5. stem cells.
Year Month COUNTRY CELLS TYPE ISI Web JOURNAL TITLE
2001 10 CA Hi, H7, H9, Private 180 Nat Biotechnol. 2001 Feeder-free growth of undifferentiated human
H14 Oct;19(10):971-4. embryonic stem cells.
2001 10 Israel HES-1 and Private 27 Hum Reprod. 2001 Effective cryopreservation of human embryonic stem
HES-2 Oct;16(10):2187-94. cells by the open pulled straw vitrification method.
2001 11 CA ? Private 24 Cancer J. 2001 Nov-Dec;7 Human embryonic stem cells: culture, differentiation,
Suppl 2:S83-93. and genetic modification for regenerative medicine
applications.
2001 12 WI Hi, H7, H9, Private 209 Nat Biotechnol. 2001 In vitro differentiation of transplantable neural
H9.2 Dec;19(12):1129-33. precursors from human embryonic stem cells.
2001 12 Israel HES-1 Federal/ 155 Nat Biotechnol. 2001 Neural progenitors from human embryonic stem cells.
Private Dec;19(12):1134-40.
2001 12 CA Hi, H7, H9 Private 95 Exp Neurol. 2001 Enrichment of neurons and neural precursors from
Dec;172(2):383-97. human embryonic stem cells.
2002 1 Australia ? Private Reprod Biomed Online. 2002 The fine structure of human embryonic stem cells.
Jan-Feb;4(1):56-61.
2002 3 Netherlands HES-2 Private 33 J Anat. 2002 Mar;200(Pt Cardiomyocyte differentiation of mouse and human
3):233-42. embryonic stem cells.
2002 3 United H7 Private 32 J Anat. 2002 Mar;200(Pt Surface antigens of human embryonic stem cells:
Kingdom 3):249-58. changes upon differentiation in culture.
2002 5 United H7 and H14 Private 49 Stem Cells. 2002;20(4):329- Preimplantation human embryos and embryonic stem
Kingdom 37. cells show comparable expression of stage-specific
embryonic antigens.
2002 7 Israel HES1 Private 58 Proc Natl Acad Sci U S A. Characterization of the expression of MHC proteins in
2002 Jul 23;99(15):9864-9. human embryonic stem cells.
Epub 2002 Jul 11.
I'.)
Yar ionth COUNTRY C E LLS TYPE IS Web JOURNAL TITLE
2002 9 Singapore HES-3 and Private 83 Nat Biotechnol. 2002 Human feeders support prolonged undifferentiated
HES-4, new Sep;20(9):933-6. growth of human inner cell masses and embryonic stem
HES cell line cells.
on FM feeders
2002 9 CA Hi, H7, and Private 78 Circ Res. 2002 Sep Characterization and enrichment of cardiomyocytes
H9, H9.1 and 20;91(6):501-8. derived from human embryonic stem cells.
H9.2
2002 9 Israel Derived Private 18 Dev Dyn. 2002 Sep;225(1):80- Integration and differentiation of human embryonic
6. stem cells transplanted to the chick embryo.
2002 10 China ? Private Zhonghua Yi Xue Za Zhi. [Human embryonic stem cell lines preliminarily
2002 Oct 10;82(19):1314-8. established in China
2002 12 WI HI, H7, H9, Federal/ 60 Nat Biotechnol. 2002 BMP4 initiates human embryonic stem cell
and H14 Private Dec;20(12):1261-4. Epub 2002 differentiation to trophoblast
Nov 11.
2003 1 United H7, H14 Federal/ 37 Nat Biotechnol. 2004 Recurrent gain of chromosomes 17q and 12 in cultured
Kingdom Private Jan;22(1):53-4. Epub 2003 human embryonic stem cells.
Dec 07.
2003 1 CA ? Private 34 Cell Transplant. 2003;12(1):1- Generation of hepatocyte-like cells from human
11. embryonic stem cells.
2003 1 CA ? Federal/ 21 Proc Natl Acad Sci U S A. Human Pumilio-2 is expressed in embryonic stem cells
Private 2003 Jan 21;100(2):538-43. and germ cells and interacts with DAZ (Deleted in
Epub 2003 Jan 2. AZoospermia) and DAZ-like proteins.
2003 1 United H7 Private APMIS. 2003 Jan;111 (1):197- Expression of Wnt and Notch pathway genes in a
Kingdom 210; discussion 210-1 pluripotent human embryonal carcinoma cell line and
embryonic stem cell.
Year Month COUNTRY CELLS TYPE ISI Web JOURNAL TITLE
2003 2 Israel HES1 Private 21 Mol Ther. 2003 Feb;7(2):281- Stable genetic modification of human embryonic stem
7 cells by lentiviral vectors.
2003 3 WI H1.1 Private 52 Nat Biotechnol. 2003 Homologous recombination in human embryonic stem
Mar;21(3):319-21. Epub 2003 cells.
Feb 10.
2003 3 MD HI aka WAO1 Federal/ 30 Stem Cells. 2003;21(2):131- Human adult marrow cells support prolonged expansion
Private 42. of human embryonic stem cells in culture.
2003 3 United ? Private 8 Cloning Stem Cells. Infection efficiency of human and mouse embryonic
Kingdom 2003;5(1):51-62 stem cells using adenoviral and adeno-associated viral
2003 4 WI H9 Federal 39 Stem Cells. 2003;21(1):111-7. High-level sustained transgene expression in human
embryonic stem cells using lentiviral vectors.
2003 5 Israel H9 clone Private 12 Stem Cells. 2003;21(3):257- Selective ablation of human embryonic stem cells
65. expressing a "suicide" gene.
2003 6 Netherlands HES-2 Federal/ 48 Circulation. 2003 Jun Differentiation of human embryonic stem cells to
Private 3;107(21):2733-40. Epub 2003 cardiomyocytes: role of coculture with visceral
May 12. endoderm-like cells.
2003 6 Israel 13, 16, H9 Private 44 Biol Reprod. 2003 Human feeder layers for human embryonic stem cells.
Jun;68(6):2150-6. Epub 2003
Jan 22.
2003 7 KY H1, H7, H9, Federal/ 29 Circ Res. 2003 Jul 1 1;93(l):32- Human embryonic stem cells develop into multiple
and H14 Private 9. Epub 2003 Jun 05. types of cardiac myocytes: action potential
characterization.
2003 7 Sweden HS181, HS207 Private 28 Hum Reprod. 2003 A culture system using human foreskin fibroblasts as
Jul;18(7):1404-9. feeder cells allows production of human embryonic stem
cells.
Year Month ICOUNTRY 'CELLS 'TYPE IS Web JOURNAL TITLE
2003 8 NY H1, HES3 Private 40 Dev Biol. 2003 Aug Molecular signature of human embryonic stem cells and
15;260(2):404-13. its comparison with the mouse.
2003 8 Canada H1 H9 Private 30 Blood. 2003 Aug 1; 102(3):906- Cytokines and BMP-4 promote hematopoietic
15. Epub 2003 Apr 17 differentiation of human embryonic stem cells.
2003 8 United ? Private 11 Cloning Stem Cells. In vitro osteogenic differentiation of human ES cells.
Kingdom 2003;5(2):149-55.
2003 9 GA BGO1, BG02, Private 27 Stem Cells. 2003;21(5):521-6. Human embryonic stem cell lines derived from
BGO3, BGO4 discarded embryos.
2003 9 Singapore HES-3 and Private 22 Stem Cells. 2003;21(5):546- Comparative evaluation of various human feeders for
HES-4 56. prolonged undifferentiated growth of human embryonic
stem cells.
2003 9 Australia ? Private 0 Reprod Biomed Online. 2003 Critical evaluation of human blastocysts for assisted
Sep;7(2):219-27. reproduction techniques and embryonic stem cell
biotechnology.
2003 10 MA H9 clone Federal 22 Proc Natl Acad Sci U S A. Differentiation of human embryonic stem cells on three-
2003 Oct 28;100(22):12741-6. dimensional polymer scaffolds.
Epub 2003 Oct 15.
2003 10 GA BG01, BG02 Private 13 BMC Neurosci. 2003 Oct Directed neuronal differentiation of human embryonic
22;4(1):27. stem cells.
2003 10 United Derived Private Reprod Biomed Online. 2003 Preimplantation genetic diagnosis as a novel source of
Kingdom Oct;7(3):353-64. embryos for stem cell research.
2003 11 WI Derived Federal/ 35 Proc Natl Acad Sci U S A. Gene expression patterns in human embryonic stem
Private 2003 Nov 11;100(23):13350-5. cells and human pluripotent germ cell tumors.
Epub 2003 Oct 31
Year Month COUNTRY CELLS TYPE ISI Web JOURNAL TITLE
2003 11 Israel H9.1 Private 7 Proc Nati Acad Sci U S A. An experimental platform for studying growth and
2003 Nov 11; 100(23):13507- invasiveness of tumor cells within teratomas derived
12. Epub 2003 Oct 22. from human embryonic stem cells.
2003 12 South Korea Derived: Miz- Federal 18 Biol Reprod. 2003 Establishment and maintenance of human embryonic
hES 1, Miz- Dec;69(6):2007-14. Epub 2003 stem cells on STO, a permanently growing cell line.
hES2, and Miz- Aug 20.
hES3
2003 12 MA H9 Federal 10 Proc Natl Acad Sci U S A. Marker succession during the development of
2003 Dec 23;100(26):15625- keratinocytes from cultured human embryonic stem
30. Epub 2003 Dec 08 cells.
2003 12 Israel H9.2, H13, 19 Private 6 Lab Invest. 2003 Human embryonic stem cells as an in vitro model for
Dec;83(12):1811-20. human vascular development and the induction of
vascular differentiation.
2003 12 South Korea MB03 Federal 3 Neurosci Lett. 2003 Dec Genetically modified human embryonic stem cells
19;353(2):91-4. relieve symptomatic motor behavior in a rat model of
Parkinson's disease.
2003 12 Australia N/A Private 3 Methods Enzymol. Isolation, characterization, and differentiation of human
2003;365:429-46. embryonic stem cells.
2003 12 Israel N/A Private 2 Methods Enzymol. Development of cardiomyocytes from human ES cells.
2003;365:461-73.
2003 12 Israel N/A Private 0 Methods Enzymol. Factors controlling human embryonic stem cell
2003;365:446-61. differentiation.
0*'
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2003 12 Russia Russian HESC-Private 0 Tsitologiia. 2003;45(12):1172- [Isolation and characterisation of continuous human
1, HESC-2, 8. embryonic stem cell lines]
HESC-3,
HESC-4
2003 12 Israel H9.2 Federal/ 0 Am J Physiol Heart Circ Assessment of the ultrastructural and proliferative
Private Physiol. 2003 properties of human embryonic stem cell-derived
Dec;285(6):H2355-63. cardiomyocytes.
2004 1 NY H1, BGN1, Private 59 Nat Med. 2004 Jan;10(1):55- Maintenance of pluripotency in human and mouse
BGN2 63. Epub 2003 Dec 21. embryonic stem cells through activation of Wnt
signaling by a pharmacological GSK-3-specific
inhibitor.
2004 1 United H9 Federal 1 Stem Cells. 2004;22(1):2-1 1. Enhancing and diminishing gene function in human
Kingdom embryonic stem cells
2004 2 CA HI, H7, H9 Private 31 Dev Dyn. 2004 Feb;229(2):259 Long-term culture of human embryonic stem cells in
74. feeder-free conditions.
2004 2 CA HI, H7, H9, Private 26 Dev Dyn. 2004 Feb;229(2):243 Properties of four human embryonic stem cell lines
and H14 58. maintained in a feeder-free culture system.
2004 3 South Korea Derived: Federal 89 Science. 2004 Mar Evidence of a pluripotent human embryonic stem cell
SCNT-hES-1 12;303(5664):1669-74. Epub line derived from a cloned blastocyst.
2004 Feb 12.
2004 3 MA HUES1 Private 46 N Engl J Med. 2004 Mar Derivation of embryonic stem-cell lines from human
through 25;350(13):1353-6. Epub 2004 blastocysts.
HUES17 Mar 03
2004 3 Israel 13, 16, H9 Federal/ 24 Biol Reprod. 2004 Feeder layer- and serum-free culture of human
Private Mar;70(3):837-45. Epub 2003 embryonic stem cells.
Nov 19.
-4
Year Month COUNTRY CELLS TYPE ISI Web JOURNAL TITLE
2004 3 CA HSF-1, HSF-6 Federal/ 14 Hum Mol Genet. 2004 Mar Unique gene expression signatures of independently-
and H9 Private 15;13(6):601-8. Epub 2004 Jan derived human embryonic stem cell lines.
28.
2004 3 Australia HES-2 and Federal/ 12 J Cell Sci. 2004 Mar 1;117(Pt Regulation of human embryonic stem cell
HES-3 Private 7):1269-80 differentiation by BMP-2 and its antagonist noggin
2004 3 United HI, H9 Federal/ 10 Stem Cells. 2004; Oct-4 knockdown induces similar patterns of endoderm
Kingdom Private 22(2):225-35. and trophoblast differentiation markers in human and
mouse embryonic stem cells.
2004 3 United Derived Private 9 Mol Reprod Dev. Expression of mRNAs for DNA methyltransferases and
Kingdom 2004 Mar; methyl-CpG-binding proteins in the human female germ
67(3):323-36. line, preimplantation embryos, and embryonic stem
cells.
2004 3 Israel Derived Private 3 Hum Reprod. 2004 Derivation of a diploid human embryonic stem cell line
Mar; 19(3):670-5. Epub 2004 from a mononuclear zygote.
Jan 29.
2004 3 South Korea Derived Federal 3 Hum Reprod. 2004 Establishment of human embryonic stem cell lines from
Mar;19(3):676-84. Epub 2004 frozen-thawed blastocysts using STO cell feeder layers.
Jan 29.
2004 3 Germany ? Private 0 ALTEX. 2004; Neurotoxicity of active compounds--establishment of
21 Suppl 3:41-8. hESC-lines and proteomics technologies for human
embryo- and neurotoxicity screening and biomarker
identification.
2004 4 MD GE01, GE09, Federal/ 18 Blood. 2004 Apr Gene expression in human embryonic stem cell lines:
BG01, BG02, Private 15;103(8):2956-64. Epub 2003 unique molecular signature.
and TE06; Dec 30.
GEOI, GE07,
and GE09
00
V_ r-f-rXhaTr A T 4TT T tI I..-
Ieat Month CUNTRY CLLS TY PE ISI Web JOURNAL TITLE
2004 4 CA HSF-6, HSF-1 Federal/ 12 Hum Mol Genet. 2004 Apr Spontaneous differentiation of germ cells from human
and H9 Private 1;13(7):727-39. Epub 2004 embryonic stem cells in vitro.
Feb 12.
2004 4 South Korea MB03 Federal 8 Neurosci Lett. 2004 Apr Generation of dopaminergic neurons in vitro from
8;359(1-2):99-103. human embryonic stem cells treated with neurotrophic
factors.
2004 4 Canada HI and H9 Private 6 Blood. 2004 Apr VEGF-A165 augments erythropoietic development from
1;103(7):2504-12. Epub 2003 human embryonic stem cells.
Dec 04.
2004 4 WI HI Federal/ 6 Endocrinology. 2004 Trophoblast differentiation in embryoid bodies derived
Private Apr;145(4):1517-24. Epub from human embryonic stem cells.
2003 Dec 18.
2004 4 South Korea Miz-HES1 Federal 3 Mol Cells. 2004 Apr Establishment of a human embryonic germ cell line and
30;17(2):309-15 comparison with mouse and human embryonic stem
cells.
2004 4 Singapore HES-3 and Private 0 Stem Cells. 2004; The transcriptome profile of human embryonic stem
HES-4 22(1):51-64. cells as defined by SAGE.
2004 5 MD HI Federal/ 17 Dev Biol. 2004 May Differences between human and mouse embryonic stem
Private 15;269(2):360-80 cells.
2004 5 MD BGO1, BGO2 Federal 10 Stem Cells. 2004; Properties of pluripotent human embryonic stem cells
22(3):292-312. BGO1 and BG02.
2004 5 Israel H9.2, H13, 16 Private 9 Stem Cells. 2004; Differentiation of human embryonic stem cells into
22(3):265-74. insulin-producing clusters.
Year Month COUNTRY CELLS TYPE ISI Web JOURNAL TITLE
2004 5 Sweden Derived: Federal/ 7 Stem Cells. 2004; Derivation, characterization, and differentiation of
SA002; Private 22(3):367-76 human embryonic stem cells.
FCO18,
AS034, and
AS038; SA121
and SA181
2004 5 Canada H9.2 and 16 Federal/ 1 Stem Cells. 2004;22(3):275- Controlled, scalable embryonic stem cell differentiation
Private 82. culture.
2004 5 Australia HES-2 Private 0 Fetal Diagn Ther. 2004 May- Human embryonic stem cells form embryoid bodies
Jun;19(3):218-23. containing visceral endoderm-like derivatives.
2004 6 South Korea SNU-hES3 Federal 9 Dev Biol. 2004 Jun Human embryonic stem cells express a unique set of
and MIZ-hES 1 15;270(2):488-98. microRNAs
2004 6 Sweden Derived: Private 6 Mol Hum Reprod. 2004 Comparative genomic hybridization and karyotyping of
HS181, HS235 Jun;10(6):461-6. Epub 2004 human embryonic stem cells reveals the occurrence of
and HS237 Mar 25. an isodicentric X chromosome after long-term
cultivation.
2004 6 Israel Derived Private 4 Differentiation. 2004 Differentiation and isolation of hepatic-like cells from
Jun;72(5):230-8. human embryonic stem cells.
2004 6 Iran Royan H1 Private 1 Differentiation. 2004 Establishment and in vitro differentiation of a new
Jun;72(5):224-9. embryonic stem cell line from human blastocyst
2004 6 Israel H9.2 Federal/ 1 Biotechnol Bioeng. 2004 Jun Bioreactor cultivation enhances the efficiency of human
Private 5;86(5):493-502 embryoid body (hEB) formation and differentiation
2004 6 Germany H1 Private 0 Cell Physiol Biochem. Beta-adrenergic and Muscarinic Modulation of Human
2004; 14(4-6):187-96 Embryonic Stem Cell-derived Cardio-myocytes.
0
Year Month COUNTRY CELLS TYPE ISI Web JOURNAL TITLE
2004 6 Japan ? Private 0 Cell Transplant. Differentiation of human and mouse embryonic stem
2004;13(3):197-211. cells along a hepatocyte lineage.
2004 6 IL HI Private Blood. 2004 Jun CD34+CD38- hematopoietic precursors derived from
1;103(11):4134-41. Epub 2004 human embryonic stem cells exhibit an embryonic gene
Feb 12. expression pattern.
2004 7 MA H9 Federal 10 Nat Biotechnol. 2004 Nanoliter-scale synthesis of arrayed biomaterials and
Jul;22(7):863-6. Epub 2004 application to human embryonic stem cells.
Jun 13.
2004 7 MA HI Private 5 J Biol Chem. 2004 Jul The Src family of tyrosine kinases is important for
23;279(30):31590-8. Epub embryonic stem cell self-renewal.
2004 May 17.
2004 7 Canada HI, H7, H9 Private 3 Stem Cells. 2004; Human embryonic stem cells possess immune-
22(4):448-56. privileged properties.
2004 7 Canada Hi, H9 Federal/ 3 Immunity. 2004 Jul; Endothelial and hematopoietic cell fate of human
Private 21(1):31-41. embryonic stem cells originates from primitive
endothelium with hemangioblastic properties.
2004 7 China Derived: HES- State 2 Chin Med J (Engl). 2004 Jul; Cryopreservation of human embryonic stem cells by
1 China 117(7):1050-5. vitrification.
2004 7 MN HI Federal/ 1 Stem Cells. 2004; Efficient transfection of embryonic and adult stem cells
Private 22(4):531-43
2004 7 MD HI Federal/ 1 Lancet. 2004 Jul Functional antigen-presenting leucocytes derived from
Private 10;364(9429):163-71 human embryonic stem cells in vitro.
2004 7 Israel H9 Federal/ 0 Nucleic Acids Res. 2004 Jul Gene trap as a tool for genome annotation and analysis
Private 29;32(13):3995-4002 of X chromosome inactivation in human embryonic
stem cells
Year Month COUNTRY CELLS TYPE ISI Web JOURNAL TITLE
2004 7 Israel H13 Federal/ 0 Stem Cells. 2004; Modeling for Lesch-Nyhan disease by gene targeting in
Private 22(4):635-41 human embryonic stem cells.
2004 7 South Korea MB03 Federal 0 Neurosci Lett. 2004 Jul 1; Enhancement of re-closure capacity by the intra-
364(2):98-100. amniotic injection of human embryonic stem cells in
surgically induced spinal open neural tube defects in
chick embryos.
2004 7 South Korea ? Federal 0 Ultrastruct Pathol. 2004 Jul- Ultrastructure of human embryonic stem cells and
Aug;28(4):229-38. spontaneous and retinoic acid-induced differentiating
cells.
2004 8 NY Hi, H9, HES- Federal/ 6 Proc Natl Acad Sci U S A. Derivation of midbrain dopamine neurons from human
3 Private 2004 Aug 24; 101(34):12543-8. embryonic stem cells.
Epub 2004 Aug 13.
2004 8 United Derived: Private 2 Stem Cells Dev. 2004 Human embryonal carcinoma stem cells: models of
Kingdom TERA2.cl.SP1 Aug;13(4):400-8. embryonic development in humans.
2.
2004 8 Sweden HS181 Private 2 Stem Cells Dev. 2004 Organized development from human embryonic stem
Aug;13(4):421-35. cells after injection into immunodeficient mice.
2004 8 Sweden HS181 Private 1 Stem Cells Dev. 2004 Culture and expansion of the human embryonic stem
Aug;13(4):337-43 cell line HS181, evaluated in a double-color system
2004 8 South Korea Miz-hES 14, - Federal Biol Reprod. 2004 Aug 18 Establishment and Maintenance of Human Embryonic
15, and -9 [Epub ahead of print] Stem Cell Lines on Human Feeder Cells Derived from
Uterine Endometrium under Serum-Free Condition.
2004 8 MD H1, H7, and Federal/ BMC Dev Biol. 2004 Aug MPSS profiling of human embryonic stem cells.
H9 Private 10;4(1): 10.
2004 9 CA HSF6 Private 6 Stem Cells. 2004;22(4):522- Maintenance of pluripotency in human embryonic stem
30. cells is STAT3 independent.
Year VILonth COIUN1IY CELLS TYPE ISI Web JOURNAL TITLE
2004 9 United H7 and H14 Federal/ 5 Stem Cells. 2004;22(5):659-68 Specific knockdown of Oct4 and beta2-microglobulin
Kingdom Private expression by RNA interference in human embryonic
stem cells and embryonic carcinoma cells
2004 9 MA H9, HSF-6 Federal 4 Stem Cells. 2004; LIF/STAT3 signaling fails to maintain self-renewal of
22(5):770-8 human embryonic stem cells.
2004 9 United Derived: hES- Private 4 Stem Cells. 2004; Derivation of human embryonic stem cells from day-8
Kingdom NCL1 22(5):790-7 blastocysts recovered after three-step in vitro culture.
2004 9 Belgium H9 Private 1 Cloning Stem Cells. Highly efficient mRNA-based gene transfer in feeder-
2004;6(3):211-6. free cultured H9 human embryonic stem cells.
2004 9 WI H1 Federal/ 1 J Am Chem Soc. 2004 Sep Arrays for the combinatorial exploration of cell
Private 8; 126(35):10808-9. adhesion.
2004 9 MA ? Private 1 Cloning Stem Cells. Derivation and comparative assessment of retinal
2004;6(3):217-45. pigment epithelium from human embryonic stem cells
using transcriptomics.
2004 9 KY H9.2 Federal/ 1 J Physiol. 2004 Sep 1;559(Pt Mechanism of spontaneous excitability in human
Private 2):479-96. embryonic stem cell derived cardiomyocytes.
Epub 2004 Jul 08.
2004 9 China ? Private 0 Yi Chuan Xue Bao. 2004 [Screening of differential genes between human
Sep;31(9):956-62. embryonic stem cell and differentiated cell]
2004 9 Singapore HES-2, HES- Private 0 Stem Cells. 2004; An efficient and safe xeno-free cryopreservation method
3, HES-4 (ES 22(5):779-89 for the storage of human embryonic stem cells.
Cell)
2004 9 United HI Private 0 Tissue Eng. 2004 Sep- In vitro differentiation and in vivo mineralization of
Kingdom Oct; 10(9-10):1518-25 osteogenic cells derived from human embryonic stem
cells.
Year Month COUNTRY CELLS TYPE ISI Web JOURNAL TITLE
2004 10 Israel H9.2 Federal/ 7 Nat Biotechnol. 2004 Electromechanical integration of cardiomyocytes
Private Oct;22(10):1282-9. Epub 2004 derived from human embryonic stem cells.
Sep 26.
2004 10 Japan H1 Federal/ 0 J Anat. 2004 Oct;205(4):247- Cytochemical and ultrastructural characterization of
Private 55. growing colonies of human embryonic stem cells.
2004 10 MN HI Federal 0 Exp Hematol. 2004 Cytokine requirements differ for stroma and embryoid
Oct;32(10):1000-9 body-mediated hematopoiesis from human embryonic
stem cells.
2004 10 Singapore H9 Private 0 In Vitro Cell Dev Biol Anim. Feeder cell density-a key parameter in human embryonic
2004 Oct;40(8):255 stem cell culture.
2004 10 GA BGOL Federal/ 0 Biochem Biophys Res Transcriptional profiling of initial differentiation events
Private Commun. 2004 Oct in human embryonic stem cells.
15;323(2):453-64.
2004 11 United H9 Federal/ 3 Dev Biol. 2004 Nov Nodal inhibits differentiation of human embryonic stem
Kingdom Private 15;275(2):403-21. cells along the neuroectodermal default pathway.
2004 11 Singapore HES-2, HES- Federal 1 Biotechnol Bioeng. 2004 Nov Expansion of pluripotent human embryonic stem cells
3, HES-4 5;88(3):321-31 on human feeders.
2004 11 WI H1 and H9 Federal 1 Biotechnol Bioeng. 2004 Nov Cryopreservation of adherent human embryonic stem
5;88(3):299-312. cells.
2004 11 GA BG01 and H1 Private 0 Biotechnol Bioeng. 2004 Nov Comparative transcriptional profiling of two human
5;88(3):273-86. embryonic stem cell lines.
2004 11 Israel H9.2, H13 Federal/ 0 Biotechnol Bioeng. 2004 Nov Three-dimensional porous alginate scaffolds provide a
Private 5;88(3):313-20. conducive environment for generation of well-
vascularized embryoid bodies from human embryonic
stem cells.
Year Month COUNTRY CELLS TYPE IS! Web JOURNAL TITLE
2004 11 KY BG01 Federal 0 J Cell Biol. 2004 Nov Selective apoptosis of pluripotent mouse and human
22;167(4):723-34. Epub 2004 stem cells by novel ceramide analogues prevents
Nov 15. teratoma formation and enriches for neural precursors in
ES cell-derived neural transplants.
2004 1 South Korea Miz-HES 1, 2, Federal 0 Stem Cells. 2004; Effects of type IV collagen and laminin on the
3 22(6):950-61 cryopreservation of human embryonic stem cells
2004 11 CA Hi, H7, and Private 0 Stem Cells. 2004;22(6):972-80 Immortalized fibroblast-like cells derived from human
H9 embryonic stem cells support undifferentiated cell
growth.
2004 12 Israel ? Private 2 Hum Reprod. 2004 Temporal gene expression during differentiation of
Dec;19(12):2875-83. Epub human embryonic stem cells and embryoid bodies.
2004 Sep 16.
2004 12 MD BGOL Private 2 Stem Cells. 2004;22(6):925-40 Dopaminergic differentiation of human embryonic stem
cells.
2004 12 IL Derived Private 1 Reprod Biomed Online. 2004 Morula-derived human embryonic stem cells.
Dec;9(6):623-9.
2004 12 WI HI Private 1 Stem Cells Dev. 2004 Maintenance of pluripotency in human embryonic stem
Dec;13(6):636-45. cells stably over-expressing enhanced green fluorescent
protein.
2004 12 Israel H9.2, H13, Private 1 Biol Reprod. 2004 Vascular development in early human embryos and in
and 16 Dec;71(6):2029-36. Epub 2004 teratomas derived from human embryonic stem cells.
Aug 18.
2004 12 China ? Private 0 Beijing Da Xue Xue Bao. 2004 [Human embryonic stem cells forming embryoid bodies
Dec;36(6):605-8 comprising multiple types of cells.]
2004 12 China HESC-1? Private 0 Zhonghua Yi Xue Yi Chuan [Molecular cloning and characterization analysis of
Xue Za Zhi. 2004 HPESCRG1, a novel gene expressed specifically in
Dec;21(6):542-7. human embryonic stem cell.]
Year Month COUNTRY CELLS TYPE ISI Web JOURNAL TITLE
2004 12 MD HI, H7, and Private 0 Stem Cells Dev. 2004 Monitoring early differentiation events in human
H9 Dec;13(6):694-715. embryonic stem cells by massively parallel signature
sequencing and expressed sequence tag scan.
2004 12 MN H9.2 Private 0 Cardiovasc Res. 2004 Dec Divergent action potential morphologies reveal
1;64(3):477-87 nonequilibrium properties of human cardiac Na
channels.
2004 12 South Korea (Miz-hES 1 Federal/ 0 Mol Cells. 2004 Dec Expression of estrogen receptor-alpha and -beta,
Private 31; 18(3):320-5. glucocorticoid receptor, and progesterone receptor genes
in human embryonic stem cells and embryoid bodies.
2004 12 South Korea Miz-hES1 Federal 0 Reproduction. 2004 Available human feeder cells for the maintenance of
Dec;128(6):727-35. human embryonic stem cells.
2004 12 Canada H9 Federal/ 0 Mol Ther. 2004 Retroviral transduction of hematopoietic cells
Private Dec; 10(6):1109-20. differentiated from human embryonic stem cell-derived
CD45(neg)PFV hemogenic precursors.
2004 12 GA BG01, BG02, Private 0 Stem Cells Dev. 2004 Karyotypic stability, genotyping, differentiation, feeder-
and BGO3 Dec;13(6):585-97. free maintenance, and gene expression sampling in three
human embryonic stem cell lines derived prior to
August 9, 2001.
2004 12 Israel HES-I Federal/ 0 Stem Cells. 2004;22(7):1246- Transplantation of human embryonic stem cell-derived
Private 55. neural progenitors improves behavioral deficit in
Parkinsonian rats.
2004 12 GA BGOL and Private 0 Stem Cells. 2004;22(7):1218- Differentiation of human embryonic stem cells to
BGO3 38. dopaminergic neurons in serum-free suspension culture.
2005 0 China Derived: cHES Private 0 Chinese Medical Journal Establishment of human embryonic stem cell line from
1 gamete donors.
XYear Month CO UNTR Y CELL TYPE ISI Web JOURNAL TITLE
2005 1 IL Derived: 18 Private 2 Reprod Biomed Online. 2005 Human embryonic stem cell lines with genetic
lines Jan;10(1):105-10. disorders.
2005 1 South Korea Miz-HES 1, 2, Federal 1 EBS Lett. 2005 Jan Contribution of the PI3K/Akt/PKB signal pathway to
3 17;579(2):534-40 maintenance of self-renewal in human embryonic stem
cells.
2005 1 Japan Derived Private 1 Mech Dev. 2005 Jan;122(1):67- Pluripotential competence of cells associated with
79. Nanog activity.
2005 1 China H9 Federal 0 Acta Biochim Biophys Sin Establishment of human embryonic stem cell line stably
(Shanghai). 2005 Jan;37(1):68- expressing Epstein-Barr virus-encoded nuclear antigen 1
73
2005 1 MD ? Private 0 Circulation. 2005 Jan Functional integration of electrically active cardiac
4; 111(1): 11-20. Epub 2004 derivatives from genetically engineered human
Dec 20. embryonic stem cells with quiescent recipient
ventricular cardiomyocytes: insights into the
development of cell-based pacemakers.
2005 1 Pennsylvania H9 Private 0 Chem Commun (Camb). 2005 Cell-permeable GPNA with appropriate backbone
Jan 14;(2):244-6. Epub 2004 stereochemistry and spacing binds sequence-specifically
Dec 02. to RNA.
2005 1 South Korea Miz-hES14, - Federal 0 Biol Reprod. 2005 Establishment and maintenance of human embryonic
15, and -9 Jan;72(1):42-9. Epub 2004 stem cell lines on human feeder cells derived from
Aug 18 uterine endometrium under serum-free condition
2005 1 Spain Derived: VAL- State 0 Fertil Steril. 2005 First derivation in Spain of human embryonic stem cell
1 and VAL-2 Jan;83(1):246-9 lines: use of long-term cryopreserved embryos and
animal-free conditions
2005 1 Israel ? Private 0 FASEB J. 2005 Jan; 19(1):147- Design principle of gene expression used by human
9. Epub 2004 Oct 21. stem cells: implication for pluripotency.
Year Month COUNTRY CELLS TYPE ISI Web JOURNAL TITLE
2005 1 CA Federal/ 0 Genomics. 2005 Jan; Identification and characterization of RNA sequences to
Private 85(1):92-105. which human PUMILIO-2 (PUM2) and deleted in
Azoospermia-like (DAZL) bind.
2005 1 United HI Federal/ 0 Stem Cells. 2005; Stably transfected human embryonic stem cell clones
Kingdom Private 23(1):124-33. express OCT4-specific green fluorescent protein and
maintain self-renewal and pluripotency.
2005 1 WI H1 and H9 Federal Blood. 2005 Jan 15;105(2):617. Human embryonic stem cell-derived CD34+ cells:
26. Epub 2004 Sep 16. efficient production in the co-culture with OP9 stromal
cells and analysis of lymphohematopoietic potential
2005 2 CA HI Private 6 Nat Med. 2005 Feb; 11(2):228- Human embryonic stem cells express an immunogenic
32. Epub 2005 Jan 30 nonhuman sialic acid.
2005 2 WI Hi, H9, H14 Private 2 Nat Methods. 2005 Feb Basic FGF and suppression of BMP signaling sustain
17;2(3):185-190 [Epub ahead undifferentiated proliferation of human ES cells.
of print]
2005 2 Singapore HES-2 Federal 1 Stem Cells. 2005 Transcriptome profiling of human and murine ESCs
Feb;23(2):166-85 identifies divergent paths required to maintain the stem
cell state.
2005 2 CA H7 Private/ 1 Glia. 2005 Feb; Human embryonic stem cells differentiate into
State 49(3):385-96. oligodendrocytes in high purity and myelinate after
spinal cord transplantation.
2005 2 Australia HES3 Private 0 Proteomics. 2005 Feb A proteome analysis of conditioned media from human
14;5(4):978-989 [Epub ahead neonatal fibroblasts used in the maintenance of human
of print] embryonic stem cells.
2005 2 Israel H9.2 Federal 0 Dev Dyn. 2005 Feb;232(2):487 Vascular gene expression and phenotypic correlation
97. during differentiation of human embryonic stem cells.
00
17 If -IrN TTTW'N TYear ivionth U UIN 1A I CU RY CLLS TYPE IS Web JOURNAL TITLE
2005 2 South Korea Miz-HES 1, 3, Federal 0 Mol Cells. 2005 Feb Comparative characteristics of three human embryonic
4 28;19(l):31-8. stem cell lines.
2005 2 South Korea Derived: Federal 0 Stem Cells. 2005 Derivation and characterization of new human
SNUhES1, Feb;23(2):211-9 embryonic stem cell lines: SNUhESi, SNUhES2, and
SNUhES2, and SNUhES3.
SNUhES3
2005 2 South Korea Derived: Miz- Federal 0 Mol Cells. 2005 Feb Efficient derivation of new human embryonic stem cell
hES 4-8, 28;19(l):46-53. lines.
10-13
2005 2 South Korea SNUhES3 Federal 0 Exp Mol Med. 2005 Feb Efficient gene delivery in differentiated human
28;37(l):36-44. embryonic stem cells.
2005 2 WI Hl.I Private 0 Stem Cells. 2005 Differentiation of human embryonic stem cells occurs
Feb;23(2):146-9. through symmetric cell division.
2005 2 WI HI and H9 Federal/ 0 Nat Biotechnol. 2005 Specification of motoneurons from human embryonic
Private Feb;23(2):215-21. Epub 2005 stem cells.
Jan 30.
2005 2 Canada HI and H9 Federal/ Blood. 2005 Feb 17; [Epub Human embryonic stem cells maintained in the absence
Private ahead of print] of mouse embryonic fibroblasts or conditioned media
are capable of hematopoietic development
2005 3 MA H9 Federal/ 0 Stem Cells. 2005;23(3):299- High-Efficiency RNA Interference in Human
Private 305. Embryonic Stem Cells.
2005 3 Australia HES3 Private 0 Nat Methods. 2005 Mar The hESC line Envy expresses high levels of GFP in all
23;2(4):259-260 differentiated progeny.
2005 3 CA H7 and H9 Private 0 Stem Cells. 2005;23(3):315- Basic fibroblast growth factor supports undifferentiated
23. human embryonic stem cell growth without conditioned
medium.
'0
Year Month COUNTRY CELLS TYPE ISI Web JOURNAL TITLE
2005 3 Japan KhES-1 Private 0 Mol Cell Biol. 2005 Octamer and Sox Elements Are Required for
Mar;25(6):2475-85. Transcriptional cis Regulation of Nanog Gene
Expression.
2005 3 Singapore H9 Private 0 Cell Biochem Funct. 2005 Mar- Reduced mitotic activity at the periphery of human
Apr;23(2):141-6. embryonic stem cell colonies cultured in vitro with
mitotically-inactivated murine embryonic fibroblast
feeder cells.
2005 3 South Korea HSF-6, SNU- Federal 0 J Neurochem. 2005 In vitro and in vivo analyses of human embryonic stem
HES-3, Miz- Mar;92(5):1265-76. cell-derived dopamine neurons.
hES-1
2005 3 United H1 and hES- Federal/ 0 Stem Cells. 2005;23(3):306- An autogeneic feeder cell system that efficiently
Kingdom NCL1 Private 14. supports growth of undifferentiated human embryonic
stem cells.
2005 3 United Derived Private 0 Reprod Biomed Online. 2005 Generation of a human embryonic stem cell line
Kingdom Mar; 10(3):390-7. encoding the cystic fibrosis mutation deltaF508, using
preimplantation genetic diagnosis.
2005 3 NY Hi, BGN1, Federal/ Development. 2005 TGF{beta}/activin/nodal signaling is necessary for the
BGN2 Private Mar;132(6):1273-82. Epub maintenance of pluripotency in human embryonic stem
2005 Feb 9 cells.
2005 3 South Korea SNUhES-3 Federal Hum Reprod. 2005 Mar 10; Cryopreservation of human embryonic stem cells
[Epub ahead of print] without the use of a programmable freezer.
2005 4 CA HSF6 Private 0 Stem Cells. 2005 Activin A maintains pluripotency of human embryonic
Apr;23(4):489-95. stem cells in the absence of feeder layers.
2005 4 China ? Private 0 Zhongguo Shi Yan Xue Ye Differentiation from human embryonic stem cells to
Xue Za Zhi. 2005 hematopoietic cells and endothelial cells.]
Apr;13(2):222-8.
0
Year MIVIo nth COUN TRY CELLS TYPE IS Web JOURNAL TITLE
2005 4 Sweden Derived: Federal/ 0 Stem Cells. 2005 Derivation of human embryonic stem cell lines in serum
HS293, Private Apr;23(4):544-9. replacement medium using postnatal human fibroblasts
HS306; as feeder cells.
HS181,
HS207,
HS235, and
HS237 in
2002; HS346,
HS351,
HS356,
HS360,
HS361,
HS362,
HS363,
HS364,
HS366, and
HS368 in
2004; HS346
2005 4 MD HI Federal/ Blood. 2005 Apr 14; [Epub Hematopoietic differentiation of human embryonic stem
Private ahead of print] cells progresses through sequential hemato-endothelial,
primitive, and definitive stages resembling human yolk
sac development.
2005 4 NY Hland HES3 Federal/ Nat Biotechnol. 2005 Apr 24; Migration and differentiation of neural precursors
Private [Epub ahead of print] derived from human embryonic stem cells in the rat
brain.
2005 4 Singapore HUES-6 Federal J Biol Chem. 2005 Apr 27; Transcriptional regulation of nanog by OCT4 and
[Epub ahead of print] SOX2.
Year Month COUNTRY CELLS TYPE ISI Web JOURNAL TITLE
2005 4 Sweden Derived: Federal/ 0 Stem Cells. 2005 High-resolution analysis of the subtelomeric regions of
SA001, Private Apr;23(4):483-8. human embryonic stem cells.
SA002,
AS034,
AS034.1
[clonally
derived from
AS034],
AS038,
SA121,
SA181,
SA240, and
SA461
2005 5 China HI Federal/ 0 Biochem Biophys Res Noggin and bFGF cooperate to maintain the
State Commun. 2005 May pluripotency of human embryonic stem cells in the
13;330(3):934-42. absence of feeder layers.
2005 5 South Korea N/A Federal Stem Cells. 2005 Methods for expansion of human embryonic stem cells.
May;23(5):605-9.
